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Background: Treatment of postoperative pain remains suboptimal. This is attributed, in part, to 
the individualized physiological and psychological perception of pain. Although the effect of 
genetic variation on pain is unequivocal, precise understating of the effect of multiple gene 
interaction is yet to be investigated. Catechol-O-methyltransferase (COMT) interacts with several 
neuroreceptors in the brain including the mu receptor (OPRM1). Hence, we sought to explore the 
gene-gene interaction effect of OPRM1 and COMT on postoperative pain and opioid dose 
required for pain management. Methods: We used genotypes and clinical data for 153 
postoperative orthopedic trauma patients. For the COMT gene four single nucleotide 
polymorphisms (rs6269, rs4633, rs4818 and rs4680), three haplotypes (ACCG, ATCA, and 
GCGG), and two diplotypes (low and high pain intensity) were considered for their interactions 
with A118G of OPRM1 on postoperative pain and opioid consumption. Data were analyzed 
using descriptive statistics and multiple regression. Analyses were repeated including only the 
Caucasian subjects. Results: For postoperative opioid consumption; a significant interaction was 
found between OPRM1 and COMT rs4680 (b=0.093, p=.037) and OPRM1 and COMT rs4633 
(b=0.097, p=.037). The interactions between OPRM1 and COMT rs6269 and OPRM1 and 
COMT diplotypes demonstrated trends toward significance (b=-0.075, p=.080 and b=0.071, 
p=.070, respectively). The results for OPRM1×COMT rs4680 and OPRM1×COMT rs4633 on 
opioid consumption were maintained even after restricting the analyses to only Caucasian 
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subjects. For postoperative pain scores, a significant interaction was found between OPRM1 and 
the GCGG haplotype of COMT (b=-0.926, p=.017). The interaction between OPRM1 and COMT 
rs4818 demonstrated a trend (b=-0.755, p=.060). When the sample was limited to only Caucasian 
subjects, only a trend was observed for the interaction effect of OPRM1 and the GCGG 
haplotype of COMT on postoperative pain (p= .070). The interactions of OPRM1×ACCG 
haplotype and OPRM1×diplotypes of COMT also showed trends toward significance (b=1.110, 
p= .058 and b=0.831, p= .050, respectively). Conclusion: OPRM1×COMT interactions may 
influence the variability in postoperative pain and response to opioids. Individualized pain 
management based on genetic variation can be an effective strategy to maximize the usefulness 
of pain management. 
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1.0  INTRODUCTION 
Pain is a subjective multidimensional human experience affecting millions of people annually in 
the United States (CDC, 2015). In spite of the development of new standards and guidelines for 
pain management and the recent evolution in the technology and pharmacology of postoperative 
analgesia, many patients still suffer pain after surgery; hence pain management protocols are 
currently insufficient. According to a national survey of 250 US adults who had undergone 
surgical procedures, approximately 80% of patients experienced acute postoperative pain, with 
most (86%) rating their pain as moderate, severe, or extreme (Apfelbaum, Chen, Mehta, & Gan, 
2003). Experiencing postoperative pain was the most common concern (59%) of patients 
(Apfelbaum et al., 2003). Inadequate relief of postoperative pain may result in many harmful 
physiological, psychological and behavioral consequences that result in increased morbidity and 
mortality as well as health care costs (Caudill-Slosberg, Schwartz, & Woloshin, 2004; Feeney, 
2004; Janssen, Spinhoven, & Arntz, 2004; Joshi & Ogunnaike, 2005). 
A challenge of pain management results from the highly individualized effect of opioids 
which causes pain relief to vary among patients. Genetic variations have been suggested as a 
possible explanation for variation in pain intensity and in response to opioid treatment.  Pain 
genetic studies have focused on single gene effects; however, pain treatment is suboptimal 
(Campa, Gioia, Tomei, Poli, & Barale, 2008; Chou, Wang, et al., 2006; Hayashida et al., 2008; 
Henker et al., 2013; Ross et al., 2008; Sia et al., 2008).  Inconsistent results have been reported 
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from those studies investigating a single gene effect. One possible explanation for this would be 
ignoring other effects such as gene-gene interactions on pain and response to opioids. Recent 
evidence suggests that the interaction between two genes may have more impact on pain 
intensity and response to opioids than single gene (Kolesnikov, Gabovits, Levin, Voiko, & 
Veske, 2011; Reyes-Gibby et al., 2007). 
Both OPRM1 (mu opioid receptor) and COMT (Catechol-O-Methyltransferase; a 
catecholamine metabolizer) contribute to the neurotransmission pathways of pain within the 
brain and spinal cord. The A118G polymorphism of OPRM1 has been shown to influence pain 
and opioid effect. The mutant G118 allele displays less mRNA expression and resultant protein 
level than A118 allele in brain tissues. It also has a structure alteration that affects its expression 
and translation into functional protein. This structural alteration translates into patients having 
G118 allele experiencing more pain and consuming higher opioid amount to achieve adequate 
pain control compared with those having the wild-type A118 allele (Chou, Yang, et al., 2006; Sia 
et al., 2008; Tan et al., 2009; Y. Zhang, Wang, Johnson, Papp, & Sadee, 2005). Val158Met is the 
most common SNP of COMT, in which the substitution of valine to methionine at codon 158 
leads to a 3- to 4-fold decrease in COMT activity (Lotta et al., 1995). The decrease in the enzyme 
activity result in a reduction in pain threshold and an increase in pain score (Zubieta et al., 2003). 
Consistent with that, patients with homozygous Met were found to have more pain and consume 
less opioids compared with homozygous Val (Kolesnikov et al., 2011; Rakvag et al., 2005). 
Physiologically, COMT interacts with several neuroreceptors, modifying function, in the 
brain including the mu opioid receptor (OPRM1). Cumulative evidence shows that COMT 
affects mu receptor (OPRM1) availability, expression and density in brain tissue by affecting 
enkephalin levels, which inversely regulate mu receptor expression (Berthele et al., 2005; 
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Kowarik et al., 2012; Zubieta et al., 2003). Thus, gene-gene interaction of OPRM1 and COMT 
may influence the human experience of pain and explain greater variability in the individual 
differences compared to using either gene alone.  
However, the interaction effect of OPRM1 and COMT on postoperative pain and 
response to opioids is not well established. Findings of prior studies have not been replicated to 
confirm their results. Thus, gene-gene interaction of OPRM1 and COMT, from both a statistical 
and biological perspective, need to be further investigated to establish the impact of this 
relationship on response to pain and pain management. 
1.1 PURPOSE 
The purpose of this study was to explore the effects of gene-gene interaction of OPRM1 and 
COMT on the inter-individual variability in postoperative pain score and opioid consumption in 
postoperative orthopedic trauma patients.  
1.2 SPECIFIC AIMS AND HYPOTHESES 
1. Explore the gene-gene interaction effect of the OPRM1 A118G SNP and COMT SNPs 
(rs6269, rs4633, rs4818 and rs4680 or Val158Met), haplotypes and diplotypes on opioid 
dose required for pain management in postoperative orthopedic trauma patients. 
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Hypothesis 1a: Patients with the combination of G118 allele of OPRM1 and 
Val158Val of COMT rs4680 will consume the largest opioid dose to control pain 
compared with other combinations. 
Hypothesis 1b: Patients with the combination of A118 allele of OPRM1 and 
Met158Met of COMT rs4680 will consume the lowest opioid dose to control pain 
compared with other combinations. 
Hypothesis 1c: Patients with a combination of High Pain Sensitivity haplotype (HPS) 
or diplotype and G118 allele of OPRM1 will consume the largest opioid dose to 
control pain compared with other combinations.  
Hypothesis 1d: Patients with the combination of Low Pain Sensitivity haplotype (LPS) 
or diplotype and A118 allele of OPRM1 will consume the lowest opioid dose to 
control that pain compared with other combinations. 
 
2. Explore the gene-gene interaction effect of OPRM1 A118G and COMT SNPs (rs6269, 
rs4633, rs4818 and rs4680 or Val158Met), haplotypes and diplotypes on postoperative 
pain score in postoperative orthopedic trauma patients. 
Hypothesis 2a: Patients with the combination of the A118 allele of OPRM1 and 
Val158Val genotype of COMT rs4680 will have the lowest pain score compared with 
other combinations. 
Hypothesis 2b: Patients with the combination of the G118 allele of OPRM1 and 
Met158Met genotype of COMT rs4680 will have the highest pain score compared 
with other combinations. 
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Hypothesis 2c: Patients with combination of Low Pain Sensitivity haplotype (LPS) or 
diplotype and A118 allele of OPRM1 will have the lowest pain score compared with 
other combinations. 
Hypothesis 3d: Patients with the combination of High Pain Sensitivity haplotype 
(HPS) or diplotype and G118 allele of OPRM1 will have the highest pain score 
compared with other combinations. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 PAIN 
Pain is one of the oldest medical problems. Tracking the history of pain over the ages revealed 
the debate and uncertainty about the nature of pain. The human definition of pain has evolved 
over time from being perceived as demons to a multidimensional neurological process that is the 
result of tissue damage (Bonica, 1991; Rey, 1993).  
In ancient times when pain was considered as evil, demons or magic. Pain was treated 
with magical ceremonies, rattles gongs and other devices which were believed to frighten painful 
devils out of a person's body (Bonica, 1991; Sabatowski, Schafer, Kasper, Brunsch, & Radbruch, 
2004). Later in Europe, religion influenced pain perception. Pain was considered a sacrificial 
offering that brought faithful believers closer to Christ. Therefore grieving pain and mourning 
were considered as practice to comfort and heal the pain (Sabatowski et al., 2004). The first 
scientific interpretation of pain was during the 5th century, when Hippocrates related the cause of 
pain to an imbalance of the four humors (blood, phlegm, yellow and black bile) (Bonica, 1991; 
Rey, 1993; Sabatowski et al., 2004). The tremendous scientific experiments and research that 
took place in the 20th century led to significant discoveries in the area of pain. Numerous pain 
concepts and theories have been developed to explain the complexity of pain. The most famous 
 7 
pain theories are; specificity theory, pattern or intensity theory, and gate-control theory (Bonica, 
1991; Dallenbach, 1939; Melzack & Wall, 1965; Rey, 1993; Sabatowski et al., 2004).  
The “Gate-Control-Theory” combined for the first time the physiological as well as the 
psychological aspects of pain perception. The theory indicated a hypothetical gate within the 
spinal cord that controls our experience of pain. The hypothetical neurological gate opens and 
closes to control the traveling of pain signals to the brain. There are two type of signals passing 
through this gate; small nerve fibers (pain pathway fibers) and large fibers (sensory and touch 
neural pathways).  The gate opens by activation of pain fiber and thus stimulating the sense of 
pain. However, the gate could be closed by stimulation of the sensory pathway with higher 
volume and intensity than the pain signals which prevent pain signals to transmit to the brain and 
consequently inhibit pain perception and vice a versa (Melzack & Wall, 1965). Accordingly, 
Melzack & Wall (1965) were the first to explain how the emotional and behavioral factors could 
increase or decrease the sensitivity of pain perception (Melzack & Wall, 1965). 
Pain is now considered as a complex neurological process that could be categorized into 
different types (nociceptive, neuropathic, and psychogenic), each with distinct etiology, 
physiology, and remedy. Nociceptive Pain (acute pain) pathway involves the four processes of 
sensory neuronal transduction, transmission, perception and modulation; injured tissues release 
sensitizing chemicals (prostaglandins, bradykinin, substance P,..., etc.) that activate the 
peripheral nociceptors and lead to action potential generation. Action potentials transmit from 
site of injury to the spinal cord then continue to the brainstem, thalamus and finally to the cortex 
where pain processing and perception occurs. In the modulation phase the body releases 
substances such as endogenous opioids which bind to opioid receptors to inhibit nociceptive 
impulses (Brunton, 2011). 
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Opioids are one of the most potent drugs used to alleviate moderate to severe pain. All 
pharmacological effects of opioids are induced by activation of opioid receptors (mu, delta, and 
kappa). Opioid receptors are 7- transmembrane G-protein-coupled receptors (GPCRs) located 
synaptically and postsynaptically along pain transmission pathways (Brunton, 2011). By binding 
with those receptors, opioids cause hyperpolarization of nerve cells, inhibition of action potential 
transmission and inhibition of presynaptic neurotransmitter release, making the cellular pain 
signal less likely to reach upper the brain regions where pain perception occurs (Brunton, 2011). 
Most currently used opioid analgesics act mainly at mu opioid receptors so from the clinical 
perspective mu receptors are the most important (Matthes et al., 1996). 
2.2 CONSEQUENCES OF UNTREATED POSTOPERATIVE PAIN 
Up to 75% of surgical patients in the US complain of inadequate pain relief after surgery (Wu & 
Raja, 2011). Inadequate relief of postoperative pain may result in harmful physiologic 
consequences including; increased risk for myocardial ischemia and infarction, impaired 
immunity and increased postoperative pulmonary infection, reduced intestinal motility causing 
nausea and vomiting, urinary retention, increased deep vein thrombosis, and thromboembolism 
(Joshi & Ogunnaike, 2005). Inadequate relief of postoperative pain may also result in 
exacerbation of acute nociceptive pain, hyperalgesia and consequently the development of 
persistent chronic pain and disability after surgery (Joshi & Ogunnaike, 2005; Kehlet, Jensen, & 
Woolf, 2006). Moreover, evidence shows that inadequately treated pain also results in many 
psychological and behavioral consequences including; anxiety, anger, and exacerbation of 
physiologic and emotional responses (Feeney, 2004; Janssen et al., 2004). 
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2.3 FACTORS AFFECTING POSTOPERATIVE PAIN PERCEPTION AND 
RESPONSE TO OPIOIDS 
Pain is a multidimensional experience. Age, gender and ethnicity are well established factors 
influencing pain perception and pain treatment (Aubrun, Salvi, Coriat, & Riou, 2005; Cepeda & 
Carr, 2003; Cepeda et al., 2001). Factors, such as emotion, cognition, behavior, and culture are 
known to influence pain response. Therefore, several studies have been focused on the different 
factors which contribute to the large inter-individual variability in pain perception and response 
to opioids and have attempted to predict such a response to ensure better pain management. (Ip, 
Abrishami, Peng, Wong, & Chung, 2009; Sommer et al., 2010).  
Preoperative pain, expected pain, surgical fear, and pain catastrophizing by subjects were 
found to be the most important predictive factors of postoperative pain (Sommer et al., 2010). A 
recent systematic review reveled that preexisting pain, anxiety, age, and type of surgery are the 
four most significant predictive factors for the intensity of postoperative pain. Furthermore, the 
type of surgery, age, and psychological distress were identified as the three most important 
predictive factors for postoperative analgesic consumption (Ip et al., 2009).  
Genetic variations have been suggested as a possible explanation for variation in pain 
intensity and response to opioids. According to the Pain Genes Database (PGD), 300 candidate 
genes were identified as pain genes based on animal research (Lacroix-Fralish, Ledoux, & 
Mogil, 2007). OPRM1 and COMT are the best studied genes associated with pain perception and 
response to opioids. Both contribute to the neurotransmission pathway of pain within brain and 
spinal cord (Shi, Cleeland, Klepstad, Miaskowski, & Pedersen, 2010). 
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2.4 MU OPIOID RECEPTOR; OPRM1 
The mu receptor, a G protein-coupled receptor, is the primary site of action for endogenous and 
exogenous opioids (Bond et al., 1998; Zadina, Hackler, Ge, & Kastin, 1997). Mu receptors are 
mainly distributed in the spinal cord, brain stem, thalamus, and cortex. Mu receptors play a 
major role in opioid-induced analgesia, depression of respiration, stimulation of nausea and 
vomiting, and opioid effects on mood and reward (Sora et al., 2001). 
OPRM1 is the gene that encodes the mu opioid receptor. Over one hundred 
polymorphisms of the OPRM1 gene have been identified (Pasternak, 2010); A118G 
polymorphism is the most common single nucleotide polymorphism (SNP) of OPRM1. A118G 
is located in exon 1 of the gene in the chromosome 6q24–25 region (Wang et al., 1994); in this 
SNP asparagine is changed to aspartic acid at position 40 of the resultant gene product. This 
results in less mRNA expression in brain tissues of G allele carriers compared to A carriers. The 
G allele also results in a 10-fold decrease in brain tissue protein levels compared with other 
OPRM1 variants (Figure 1) (Y. Zhang et al., 2005). 
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Figure 1: OPRM1 expression in brain; tested with [3H]diprenorphine binding and Western blotting 
Figure 1 was originally published in the Journal of Biological Chemistry. Zhang et al. Allelic Expression Imbalance of   
Human mu Opioid Receptor (OPRM1) Caused by Variant A118G. 2005; VOL.280, pp. 32618-32624© the American 
Society for Biochemistry and Molecular Biology. 
 
The G118 has a secondary structure alteration. First, G118 indicated a well predicted 
helix in the mRNA that does not exist in the other variant structures. Second, mRNA structures 
for OPRM1 variants commonly contain a loop motif that does not appear in G118 structure 
(Figure 2). This structural alteration in G118 mRNA affects its expression and translation into 
functional protein (Y. Zhang et al., 2005). 
 
Figure 2: Secondary structures for 4 possible substitutions at position 118 in OPRM1 mRNA  
Figure 2 was originally published in the Journal of Biological Chemistry. Zhang et al. Allelic Expression Imbalance of Human 
mu Opioid Receptor (OPRM1) Caused by Variant A118G. 2005; VOL.280, pp. 32618-32624© the American Society for 
Biochemistry and Molecular Biology. 
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Given this, the functional effects of the A118G polymorphism have been demonstrated in 
the clinical setting in which the patients who are homozygous for the variant G experience more 
pain and need higher morphine doses to achieve adequate postoperative pain control compared 
with those who are homozygous for the wild-type A118 (Chou, Yang, et al., 2006; Sia et al., 
2008; Tan et al., 2009). 
2.5 CATECHOL-O-METHYLTRANSFERASE; COMT 
Catechol-O-methyltransferase (COMT) is one of several enzymes responsible for metabolizing 
and degrading catecholamines, such as dopamine, epinephrine, and norepinephrine, which 
influence the opioids pathway. Catechol-O-methyltransferase is coded by the COMT gene which 
is located on chromosome 22 (22q11.21).  COMT Val158Met is the most common SNP of 
COMT, in which the substitution of valine to methionine at position 158 lead to reduction in 
thermal stability of the COMT protein and a 3- to 4-fold decrease in the enzyme activity (Lotta et 
a l., 1995). Consequently, Met/Met genotype is associated with the lowest activity of COMT 
enzyme, followed by Met/Val and Val/Val genotype with the intermediate and the highest 
activities, respectively. 
While it is well known that COMT influences pain sensitivity and perception, the exact 
underlying mechanism is still not well understood. It has been shown that the decrease in enzyme 
activity reduces the content of enkephalins in certain brain regions (Zubieta et al., 2003). 
Moreover, it affects opioid neurotransmitter pathways by increasing mu opioid receptors 
expression and density in the brain and decreasing their activation (Kowarik et al., 2012; Zubieta 
et al., 2003). 
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Another suggested mechanism is that the reduction in COMT activity leads to increased 
tonic dopamine (extrasynaptic) level. The high tonic dopamine level inhibits phasic dopamine 
(synaptic) which reduces postsynaptic D2 receptors activation and descending inhibition, leading 
to a reduction in pain threshold and an increase in pain sensitivity (Zubieta et al., 2003). Others 
have suggested that the elevation in catecholamine levels caused by the inhibition in COMT 
enzyme activity leads to activation of β2 and β3 adrenergic receptors. Activation of these 
receptors also leads to increaseed pain sensitivity (Khasar, Green, Miao, & Levine, 2003; 
Nackley et al., 2006). In view of that, clinical studies have shown the patients with homozygous 
Met experience more pain compared with homozygous Val and heterozygous variant 
(Kolesnikov et al., 2011; Rakvag et al., 2005). 
Other SNPs in the COMT gene were also found to be associated with pain sensitivity 
including rs6269, rs4633 and rs4818 (Lee, Delaney, Keogh, Sleeman, & Shorten, 2011; F. Zhang 
et al., 2014). rs6269 (A/G) is located in the promoter region of COMT gene, whereas rs4633 
(C/T) and rs4818 (C/G) are located in the coding region at codons His62His and Leu136Leu, 
respectively. Although those SNPs are synonymous (not causing a change in the amino acid), 
they have a profound effect on maintaining mRNA secondary structure and mRNA stability 
(Nackley et al., 2006). 
It has been found that postoperative patients who carried GG of rs6269 and GG of rs4818 
experienced the lowest pain at rest and on movement after third molar (M3) extraction compared 
with patients homozygous for the common alleles (Lee et al., 2011). On the other hand, 
postoperative patients who carried AA of rs6269, TT of rs4633 and CC of rs4818 experienced 
lowest pain intensity before and one year after lumbar discectomy (Rut et al., 2014).   
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2.5.1 COMT haplotypes 
Haplotype is a set of closely linked SNPs on the chromosome that are inherited as a unit. 
Diatchenko used the four COMT SNPs; rs6269, rs4633, rs4818, and rs4680 to define three major 
pain-sensitivity haplotypes in normal volunteers. The three COMT haplotypes were designated as 
low pain sensitivity (LPS; GCGG), average pain sensitivity (APS; ATCA) and high pain 
sensitivity (HPS; ACCG) (Diatchenko et al., 2005). COMT haplotypes vary with respect to 
mRNA secondary structures and subsequently the amount of translated protein. The HPS local 
stem-loop structure has a higher folding potential compared with LPS and APS haplotypes. 
Accordingly, HPS has longest, most stable structure associated with the lowest protein levels and 
enzymatic activity and thus the highest pain sensitivity (Nackley et al., 2006). Figure 4 (B) 
shows the local stem-loop structures associated with each of the three COMT haplotypes, (C and 
D) shows the enzymatic activity and protein levels in cells expressing COMT. 
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Figure 3: Common haplotypes of the human COMT gene (LPS, APS, and HPS) mRNA secondary 
structure and enzymatic activity 
Figure 3 was originally published in the American Association for the Advancement of Science. AAAS. Nackley et al. Human 
Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure 2006; Vol. 314 
no. 5807 pp. 1930-1933© AAAS. 
 
Nackley and colleagues suggested that COMT haplotypes, rather than a single SNP, 
better account for the variability in pain sensitivity. The combinations of SNPs in haplotypes 
result in synergistic effects on protein function (Nackley et al., 2006). Therefore, the interaction 
of the Val158Met SNP with other known COMT SNPs have a greater effect on the mRNA 
structure, and subsequently the efficacy of protein translation and enzyme functions (Diatchenko 
et al., 2006; Diatchenko et al., 2005; Nackley et al., 2006). For instance, none of COMT SNPs 
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(rs6269, rs4633, rs4818 and rs4680) were associated with variable postoperative fentanyl 
consumption. However, COMT  haplotypes constructed by those SNPs were significantly 
associated with fentanyl consumption at 24 and 48 hours after surgery (F. Zhang et al., 2014). 
COMT diplotypes, combinations of haplotypes, were also found to be associated with 
pain sensitivity. Diatchenko et al. found that individuals with the HPS/APS diplotype were the 
most responsive to thermal painful stimuli and individuals with the LPS/LPS diplotype were the 
least responsive. However, COMT diplotypes were not associated with either mechanical or 
ischemic pain (Diatchenko et al., 2006). Moreover, George et al. found that COMT high pain 
sensitivity diplotype (APS/HPS, HPS/APS, HPS/HPS or APS/APS) and pain catastrophizing 
interactions were associated with higher pain intensity and greater risk of experiencing persistent 
pain following surgery compared with the low pain sensitivity diplotype (HPS/LPS, APS/LPS, 
LPS/LPS, or LPS/rare) (George et al., 2014). 
2.6 OPRM1 AND COMT MAIN EFFECTS; EVIDENCE AND GAPS IN PAIN 
LITERATURE 
OPRM1 and COMT are considered key genes in predicting pain perception and opioid efficacy. 
Several genetic studies have been conducted to explore the association between the single gene 
effects of OPRM1 or COMT on the variability in pain and response to opioids. However, overall 
contradictory results have been reported (Chou, Yang, et al., 2006; Fernández-de-las-Peñas et al., 
2013; Janicki et al., 2006; Kambur et al., 2013; Rakvag et al., 2008; Sia et al., 2013). 
Association studies investigating OPRM1 A118G found that G118 allele patients have 
higher postoperative pain score than those having the A118 allele (Sia et al., 2008; Sia et al., 
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2013; Tan et al., 2009; F. Zhang et al., 2013). However; other studies did not find any 
differences in the postoperative pain score among the A118 allele and G118 allele patients 
(Wang, et al., 2006; Chou, Yang, et al., 2006; Janicki et al., 2006; Kolesnikov et al., 2011; Liao 
et al., 2013). While some studies found that patients who are homozygous for the variant G need 
higher opioid doses to achieve adequate postoperative pain control compared with those who are 
homozygous for the wild-type A118 (Chou, Wang, et al., 2006; Hayashida, et al., 2008; Sia, et 
al., 2008; Tan, et al., 2009). Others did not find significant differences among OPRM1 
polymorphisms (Coulbault et al., 2006; Henker et al., 2013; Janicki et al., 2006; Kolesnikov et 
al., 2011). Table 1 summarizes studies investigating the association of OPRM1 A118G 
polymorphisms with pain perception and response to opioids. 
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Table 1: Genetic association studies of OPRM1 A118G polymorphism with pain and opioid consumption 
Study Country n  Gender Ethnic Group n 
Medical 
condition 
Phenotype AA n(%) AG n(%) GG n(%) Findings 
Landau  et 
al. (2004) 
Mixed 
Genea, 
Switzerland. 
New York, 
USA. 
 
181 
 
Female=181 Mixed 
Caucasian 
114 
Hispanic 67 
Geneva 
Caucasian 
84(61%) 
Hispanic 
53(39%) 
New York  
Caucasian 
30(68%) 
Hispanic 
14(32%) 
Normal Birth 
Delivery 
Genotype 
distribution 
T=121 
Geneva  
89 (65%) 
New York 
32 (72%) 
Caucasian  
78 (68%) 
Hispanic  
43 (64%) 
T=52 
Geneva  
42 (31%) 
New York 
10 (23%) 
Caucasian  
31 (27%) 
Hispanic  
21 (31%) 
T=8 
Geneva 
 6(4%) 
New York 
2(5%) 
Caucasian  
5(4%) 
Hispanic  
3 (4%) 
Describe 
genotype 
frequency 
among 
groups. 
Klepstad et 
al. (2004) 
 
Norway 99 Male=62 
Female=37 
Norwegian 
Caucasian 
Cancer 
patients 
Pain and 
morphine 
consumption  
 
78(79%) 17(17%) 4(4%) A118G 
patients have 
higher pain 
score 
compared 
with A118A 
or G118G. 
G118G 
patients 
consumed 
larger 
morphine 
dose 
compared 
with A118A 
or A118G. 
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Janicki et 
al. (2006)  
USA 101 Male=23 
Female=78 
Mixed  
Caucasian 
95(94%) 
Black 2 (2%) 
Hispanic 4 
(4%) 
laparoscopic 
abdominal 
surgery 
Pain and 
morphine 
consumption  
 
70 (69.2%) 30 (29.7%) 1 (1%) No 
statistically 
significant 
differences 
among 
groups. 
Coulbault 
et al. 
(2006)  
France 74 Male =44 
Female =30 
 
Mixed 
Caucasian 
(70) 
Black (1) 
Biracial(black 
and 
Caucasian) 
(3) 
abdominal 
surgery with 
a colorectal 
or 
coloanal 
anastomosis 
Morphine 
consumption  
 
57(77%) 15(20%) 2(3%) No 
statistically 
significant 
differences 
among 
groups. 
Chou et al. 
(2006)  
 
Taiwan 120 Male=31 
Female=89 
Taiwanese Total knee 
arthroplasty 
Morphine 
consumption  
Pain 
 
74(62%) 
 
33(27%) 
 
13(11%) 
 
G118G 
patients 
consumed 
larger 
morphine 
dose 
compared 
with A118A 
or A118G. 
No 
significant 
differences 
in pain 
scores 
among 
groups. 
Chou et al. 
(2006) 
Taiwan 80 Female=80 Taiwanese Total 
abdominal 
hysterectomy. 
Morphine 
consumption  
 
43(53.7%) 19(23.8%) 18(22.5%) G118G 
patients 
consumed 
larger 
morphine 
dose 
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compared 
with A118A.  
Reyes-
Gibby et 
al.(2007) 
 
Norway 207 Male=116 
Female=91 
Caucasian Cancer 
patients 
Pain and 
morphine 
consumption  
 
166(80%) 36(17%) 5(3%) G118G 
patients 
consumed 
larger opioid 
dose 
compared 
with A118A. 
No 
significant 
differences 
in pain 
scores 
among 
groups. 
Campa et 
al. (2008) 
Italy 138 Male =62 
Female =76 
 
Italian from 
Caucasian 
origin 
Cancer 
patients 
 
Pain 106(77%) 22(16%) 10(7%) G118 allele 
patients have 
higher pain 
score than 
A118 allele. 
Sia et al. 
(2008)  
Singapore 588 Female=588 Chinese 
Singaporean 
Caesarian 
Section 
Pain and 
morphine 
consumption  
 
271(46%) 234(40%) 80(14%) G118G 
patients have 
higher pain 
scores and 
consumed 
larger 
morphine 
doses 
compared 
with A118A. 
Hayashida 
et al. 
(2008) 
Japan 138 Male =79 
Female =59 
 
Japanese Major open 
abdominal 
surgery 
Morphine or 
Fentanyl 
consumption  
 
41(29.7%) 70(50.7%) 27(19.6%) G118G 
patients 
consumed 
larger opioid 
dose 
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compared 
with A118A 
or A118G. 
 
Tan et al. 
(2009)  
Singapore 994 Female=994 Mixed 
Chinese 
620(62.1%) 
Malays241 
(24.1%) 
Indian137 
(13.7%) 
Caesarian 
Section 
Pain and 
morphine 
consumption  
 
 
389(39%) 435(44%) 170(17%) G118G 
patients have 
higher pain 
scores and 
consumed 
larger 
morphine 
doses 
compared 
with A118A. 
Kolesnikov 
et al. 
(2011)  
 
Estonia 102 Male=45 
Female=57 
Estonian or 
Russian 
descent 
Abdominal 
radical 
prostatectomy 
or 
hysterectomy 
Pain and 
morphine 
consumption  
 
80(80.3%)  17(16.8%)  3(2.9%)  No 
statistically 
significant 
differences 
among 
groups. 
Henker et 
al. (2012) 
United 
States 
68 Male=57 
Female=22 
Caucasian Surgical 
procedures 
for 
orthopedic 
trauma 
Pain and 
morphine 
consumption  
 
51(75%) 15(22%) 2(3%) A118 allele 
patients have 
higher pain 
score than 
G118 allele. 
No 
statistically 
significant 
differences 
in morphine 
consumptiom 
among 
groups. 
Landauet 
al. (2012) 
United 
States 
105 Female=105 Mixed 
Hispanic 39 
(37%) 
Labor Analgesic 
success 
(Numerical 
59 (60%) 34 (35%) 5 (5%) No 
statistically 
significant 
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Caucasian 33 
(31%) 
Asian 
26(25%) 
Other 7(7%) 
Verbal Pain 
Scale score 
≤ 10/100 15 
minutes 
after the 
dose of 
fentanyl) 
differences 
among 
groups. 
Gong et al. 
(2013) 
China 112 Male=75 
Female=37 
Chinese Cancer 
patients 
Opioid 
consumption 
44(39%) 50(45%) 18(16%) G118G and 
A118G 
patients 
consumed 
larger opioid 
dose 
compared 
with A118A 
Liao et al. 
(2013) 
China 97 Male=60 
Female=37 
Chinese Radical 
gastrectomy 
Pain and 
morphine 
consumption  
 
42(43%) 41(42%) 14(15%) No 
statistically 
significant 
differences 
among 
groups. 
Zhang et 
al. (2013) 
China 96 Female=96 Chinese Caesarian 
Section 
Pain and 
fentanyl 
consumption  
 
35(36.5%) 45(46.9%) 16(16.7%) G118G 
patients have 
higher pain 
score and 
consumed 
larger 
fentanyl 
doses 
compared 
with A118G 
or A118A. 
Zhang et 
al. (2013) 
China 128 Male=76 
Female=52 
Chinese Radical 
gastrectomy 
fentanyl 
consumption 
54(42.2%) 53(41.4%) 21(16.4%) No 
statistically 
significant 
differences 
 23 
among 
groups. 
Sia et al. 
(2013) 
Singapore 973 Female=973 Mixed 
Chinese 
755(77.6%) 
Malays 
136(14%) 
Asian Indian 
82(8.4%) 
Abdominal 
hysterectomy 
Pain and 
morphine 
consumption  
 
354(36.4%) 474(48.7%) 145(14.9%) G118G 
patients have 
higher pain 
scores and 
consumed 
larger 
fentanyl 
doses 
compared 
with A118G 
or A118A. 
Cajanus et 
al. (2014) 
Finland 993 Female=993 Finns Breast cancer 
surgery 
(breast 
resection or 
mastectomy 
with axillary 
surgery) 
Pain and 
oxycodone 
consumption  
 
631(63.5%) 327(32.9%) 35(3.5%) G118 allele 
patients have 
higher pain 
score and 
consumed 
larger opioid 
dose than 
A118 allele. 
n= Sample size included in the analysis , T= Total 
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Previous studies investigating the association between COMT Val158Met and 
postoperative pain and response to opioids have also had conflicting results (Ahlers et al., 2013; 
Henker et al., 2013; Ross et al., 2008; Rut et al., 2014). It has been found that patients with 
Met158Met genotype experience significantly more pain compared to those with Val158Val and 
Val158Met genotypes (Ahlers et al., 2013; Fernandez-de-las-Penas et al., 2012; Henker et al., 
2013; Kolesnikov et al., 2011). However, others did not find this association (Kambur et al., 
2013; Rakvag et al., 2005; Rakvag et al., 2008; Ross et al., 2008; Rut et al., 2014). In terms of 
opioid consumption, it has been reported that patients with Val158Val consume higher amounts 
of opioid compared to those with the Met158Met and Val158Met genotypes (Rakvag et al., 
2008; Reyes-Gibby et al., 2007) However, others did not find significant differences among 
COMT polymorphisms (Kambur et al., 2013; Kolesnikov et al., 2011). Table 2 summarizes 
studies investigating the association of COMT Val158Met polymorphisms with pain perception 
and response to opioids. 
In regard to COMT haplotypes, it has been found that patients having the ACCG 
haplotype reported higher postoperative pain and consumed more opioids than GCGG and 
ATCA (Rut et al., 2014; F. Zhang et al., 2014), whereas Henker et al. found that the common 
haplotype GCGG was associated with highest postoperative pain score and morphine 
consumption compared with other haplotypes in orthopedic trauma surgery patients (Henker et 
al., 2013).  Kambur et al. did not find any association between the COMT haplotypes and pain 
sensitivity (Kambur et al., 2013) 
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Table 2: Genetic association studies of COMT Val158Met polymorphism with pain and opioid consumption 
Study 
 
Country 
 
n 
 
Gender Ethnic Group n 
Medical 
condition 
Phenotype  Met/Met 
(AA) 
n(%) 
Val/ 
Met(AG) 
n(%) 
Val/Val 
GG 
n(%) 
Findings 
Rakvag et 
al. (2005) 
Norway 207 Male=117 
Female=90 
Caucasians Cancer 
patients 
Pain and 
morphine 
consumption  
 
67(32%) 96(47%) 44(21%) Val158Val  
consumed 
larger 
morphine 
doses 
compared 
with 
Met158Val or 
Met158Met. 
No  
significant 
differences in 
the pain score 
amonge 
groups. 
Kim et al. 
(2006) 
United 
States 
112 Male=52 
Female=60 
European 
Americans 
Oral surgery Pain Met allele frequency (0.46) 
Val allele frequency (0.54) 
No 
statistically 
significant 
differences 
among 
groups. 
Lee et al. 
(2010) 
Ireland 98 Male=39 
Female=59 
Caucasian of 
Irish ancestry. 
Third Molar 
(M3) 
extraction 
Pain Not specified  No 
statistically 
significant 
differences 
among 
groups. 
Kolesnikov 
et al. 
(2011) 
Estonia 102 Male=45 
Female=57 
Estonian or 
Russian 
descent 
Abdominal 
radical 
prostatectomy 
Pain and 
morphine 
consumption  
22(21.6%) 
 
54(52.8%) 
 
26(25.6%) 
 
Met158Met 
patients have 
higher pain 
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or 
hysterectomy 
 score 
compared 
with 
Val158Val. 
No 
significant 
differences in 
opioid 
consumptipon 
among 
groups. 
Henker et 
al. (2012) 
United 
States 
73 Male=57 
Female=22 
Caucasian Surgical 
procedures 
for 
orthopedic 
trauma 
Pain and 
morphine 
consumption  
 
22(30%) 27(37%) 24(33%) Met158Met 
patients had 
higher pain 
scores and 
consumed 
larger 
morphine 
doses 
compared 
with 
Met158Val or 
Val158Val. 
Fernandez-
de-las-
Penas et al. 
(2012) 
Spain 128 Female=128 Caucasian Cancer 
patients, post 
mastectomy  
Post 
mastectomy 
pain 
30(23%) 64(50%) 34(27%) Met158Met 
patients had 
higher  neck 
pain intensity 
compared 
with 
Val158Met or 
Val158Val.  
Ahlers et 
al. (2013) 
Netherlands 117 Male=85 
Female=32 
Mixed  
Caucasian=115 
African 
American=1 
Asian=1  
Cardiac 
procedure  
pain 21(18%) 66(56%) 30(26%) Met158Met 
patients had 
higher pain 
score during 
cardiac 
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procedure 
compared 
with 
Met158Val or 
Val158Val. 
Kambur et 
al. (2013) 
Finland 1000 Female=1000 Finns Cancer 
patients, post 
mastectomy 
or breast 
conserving 
surgery 
Pain 
oxycodone 
consumption 
Met allele frequency (0.543) 
Val allele frequency (0.457) 
No 
statistically 
significant 
differences 
among 
groups. 
Fernandez-
de-las-
Penas et al. 
(2013) 
Spain 109 Female=109 Caucasian Carpal 
Tunnel 
Syndrome 
Pain 23(21%) 46(42%) 40(37%) Met158Met 
patients had 
higher  pain 
scores 
compared 
with 
Val158Met or 
Val158Val. 
 28 
The inconsistent findings from previous work on OPRM1 and COMT have resulted in an 
insufficient understanding of the genetic basis of the individualized variability in pain perception 
and opioid responsiveness. Possible explanations for these inconsistencies include; first, 
heterogeneous samples. Although past research has revealed the role of ethnicity in pain 
perception and expression as well as response to pain treatment (Campbell & Edwards, 2012; 
Campbell, Edwards, & Fillingim, 2005; Cepeda et al., 2001), many studies included different 
racial/ethnic groups, e.g., subjects who were Caucasian, Black, Hispanic, and/or even biracial 
(Caucasian and Black) (Coulbault, et al., 2006; Janicki, et al., 2006).  One study recruited a 
mixed sample of Chinese, Malays, and Indians (Tan, et al., 2009). Second, prior studies enrolled 
subjects with varied diagnoses and acuity. For instance, studies in cancer patients included lung, 
breast, and gastrointestinal cancer (Klepstad, et al., 2004; Rakvag, et al., 2005; Rakvag, et al., 
2008; Ross, et al., 2008) or different surgical operations, e.g., abdominal radical prostatectomy or 
hysterectomy (Kolesnikov, et al., 2011), or varied procedures, e.g., gastric bypass, 
cholecystectomy, tubal ligation, diagnostic, and hernia repair (Janicki, et al., 2006). Third, the 
relatively small sample sizes in prior studies might not have the sufficient statistical power to 
adequately detect the differences among polymorphisms. In addition, the low frequency of the 
rare G118 allele in some of prior studies investigating OPRM1 A118G might also reduce the 
statistical power. Finally, prior studies considered the effect of individual genes or haplotypes 
ignoring the possible effect of their interactions. Since single gene effects alone may not be 
responsible for all variations in pain and opioid responses, the interaction of various pain genes 
may ensure better explanation for wide variability in pain and response to opioid therapy 
(Kolesnikov et al., 2011; Reyes-Gibby et al., 2007).   
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2.7 GENE-GENE INTERACTIONS 
The gene interaction definition takes into account both biological and statistical interactions. 
Although, there is no universally accepted definition of interaction in either biology or statistics, 
the frequently used biological definition of gene-gene interaction is the interaction between 
alleles at different loci. From a statistical standpoint, interactions represent the deviation from a 
statistical additive mode that describes how two or more variables predict a phenotypic outcome 
(X. Wang, Elston, & Zhu, 2010). 
Gene-gene interactions play an important role in predicting complex pharmacologic 
treatment response and mechanisms (Lane, Tsai, & Lin, 2012). It has helped in predicting high 
risk individuals for drug under-treatment or over-treatment. Evidence has shown that gene-gene 
interaction has been significantly associated with treatment responsiveness of various drugs 
including; antidepressant drugs (Horstmann et al., 2010; Lin et al., 2009), antipsychotic drugs 
(Liou et al., 2012), IFNa and ribavirin for treating Chronic Hepatitis C (CHC) (Lin, Hwang, & 
Chen, 2007), Sibutramine for weight loss (Hsiao, Wu, Hwang, Huang, & Lin, 2010) , albuterol 
for asthma treatment (Choudhry et al., 2010; Corvol et al., 2009), and methotrexate for 
rheumatoid arthritis therapy (Sharma et al., 2008). 
2.7.1 OPRM1 and COMT gene-gene interaction 
Both OPRM1 and COMT contribute to the neurotransmission pathway of pain within the brain 
and spinal cord. Physiologically, COMT Val158Met interacts with several neuroreceptors, 
modifying function in the brain including the mu opioid receptor (OPRM1). Cumulative 
evidence shows that COMT Val158Met affects mu receptor (OPRM1) availability, expression 
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and density in brain tissue by affecting enkephalin levels, which inversely regulate mu receptor 
expression. Accordingly, the number of mu-opioid receptor binding sites is affected by COMT 
Val158 Met polymorphism such that COMT Met158 allele carriers that are significantly 
associated with the highest mu receptor expression and lowest enkephalin peptide levels 
compared with other COMT Val158 Met genotypes. (Berthele et al., 2005; Kowarik et al., 2012; 
Zubieta et al., 2003). The following sections briefly describe some of the evidences for the 
biological interaction between COMT and mu receptor (OPRM1); 
COMT Val158Met has been shown to affect the number of binding sites of mu opioid 
receptors using Positron Emission Tomography (PET) and the radiotracer [11C] carfentanil, a 
mu receptor ligand. COMT Met158 homozygotes demonstrated the highest binding potential of 
[11C] carfentanil followed by heterozygotes then the Val158 homozygotes. The authors 
hypothesized that the high levels of dopamine cause by Met at position 158 in the COMT protein 
led to a reduction in enkephalin levels and consequently, mu receptor expression is upregulated 
(Zubieta et al., 2003). 
Berthele et al. used another method, ligand binding autoradiography ([3H] DAMGO 
receptor) in post-mortem tissue, to confirm the effect of COMT Val158Met polymorphism on mu 
receptor binding site expression in the human brain (Figure 4). It has been found that COMT 
Met158 allele was associated with a higher expression of mu binding sites in the caudate 
nucleus, the nucleus accumbens and the mediodorsal nucleus of the thalamus. Consistent with of 
Zubieta findings, the availability of mu receptor binding sites is affected by the Val158Met 
polymorphism of COMT gene (Berthele et al., 2005) 
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Figure 4: COMT Val158Met genotype associated differential expression of mu receptor binding sites 
               Figure shows autoradiographs depict [3H] DAMGO ligand-binding in brain tissues. Gray values correlate with 
increasing amounts of receptor ligand bound. Copyright © 2015 Elsevier Ireland Ltd. 
 
Recently, the effect of the COMT Val158Met polymorphism on mu receptor was 
investigated using semiquantitative immunostaining in human post-mortem brain tissue. It has 
been found that the Met158 homozygotes expressed significantly more mu receptor protein than 
Val158 homozygotes in human basal ganglia and thalamic tissues (Figure 5 “G and J” vs “I and 
L”). Moreover, the lowest levels of enkephalin peptide were found in Met158 homozygotes 
tissues, whereas Val158 homozygotes showed the highest peptide levels (Figure 5 “A and D” vs 
“C and F”). Accordingly, authors suggested that the COMT Val158Met polymorphism might 
influence the mu receptor expression through use-dependent down/up-regulation secondary to 
altered enkephalin levels (Kowarik et al, 2012). 
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Figure 5: Met-enkephalin and mu receptor immunohistochemistry in brain tissues 
        Arrows highlight somata and neuropil immunoreactive for met-enkephalin or the mu opioid receptor in Cortex (A, G), basal 
ganglia (BG) (B, H), and mediodorsal nucleus of the thalamus (Th) (C, I). COMT Val158Met genotype related MOP receptor 
protein and met-enkephalin expression is shown in the macroscopic view of immunohistochemical stainings in the mediodorsal 
nucleus (MD) of the thalamus (Enkephalin D-F, MOP J-K). Increasing grey values correlate with increasing amounts of protein 
expression. Copyright © 2015 Elsevier Ireland Ltd. 
2.7.2 OPRM1 and COMT interaction effect:  evidence and gaps in pain literature 
Few studies have investigated the association between OPRM1 and COMT in relation to 
postoperative pain perception and response to opioids (Kolesnikov et al., 2011; Landau, Liu, 
Blouin, & Carvalho, 2013). Kolesnikov et al. investigated the combined effect of OPRM1 
A118G and COMT Val 158Met on pain perception and opioid response in a sample of 102 
postoperative patients (Kolesnikov et al., 2011). The combined effect of OPRM1 A118G and 
COMT Val158Met was associated with significant variability in morphine consumption during 
the first 48 hours post abdominal surgery (radical prostatectomy or hysterectomy), where the 
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patients with A118G and Val158Met combination needed significantly fewer morphine doses, 
approximately 18% less morphine, during the first 48 hours postoperatively compared with  
OPRM1 A118A (Kolesnikov et al., 2011). Several limitations have been identified; first, the 
authors used different surgical models (prostatectomy or hysterectomy), which may influence the 
study results by causing different levels of pain for males and females and therefore increasing 
the variability in morphine consumption. Second, the continuous morphine infusion used in the 
study design may have masked a possible genetic effect on morphine efficacy and making it 
more difficult to detect any possible differences in the patient-administered analgesic bolus. 
Third, when authors analyzed combined effects of OPRM1 and COMT on morphine 
consumption, they only compared morphine dose among the combined A118G/Val158Met 
carriers versus all OPRM1 A118A carriers irrespective of COMT genotype. Lastly, the authors 
considered a single COMT SNP, not haplotypes, in their analyses though evidence suggests that 
COMT haplotypes rather than a single SNP better account for the variability in pain sensitivity 
(Diatchenko et al., 2006; Diatchenko et al., 2005; Landau, Ortner, & Carvalho, 2011; Nackley et 
al., 2006; Rakvag et al., 2008). 
Recently, Landau et al investigated the effect of COMT and OPRM1 on analgesic 
response to intravenous fentanyl during labor and delivery and  found that women with the 
combination of OPRM1 AA and COMT Met/Met have lower decrease in numerical verbal pain 
score (NVPS) at 15 minutes after IV fentanyl dose compared to other combinations. There was 
no significant differences in term of analgesic response to IV fentanyl between women with 
OPRM1 AA and COMT Met/Met combination compared to women with any other allelic 
combination (Landau, Liu, Blouin, & Carvalho, 2013).  
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2.8 SIGNIFICANCE AND INNOVATION 
The response to opioid treatment for acute or chronic pain is highly individualized and varies 
among patients. This variability interferes with optimal pain management and creates risk for 
undertreating or over-treating pain. Both the undertreatment and overtreatment of pain are 
associated with adverse outcomes, e.g., inadequate pain relief, respiratory depression, or even 
death (Webster et al., 2011).  
By considering genetic factors that influence pain response and opioid effectiveness, 
high-risk individuals for opioid mismanagement can be identified. Consequently, opioid therapy 
can be individualized for better pain management, effective postoperative analgesia and 
preventing serious adverse events. Therefore, the results of this study are significant. They will 
improve our understanding of pain perception and response to opioids and they will improve 
strategies used for pain management of post-operative patients, providing a platform for safer, 
more efficacious opioid dosing. This study represents a first step towards individualized 
medicine in the post-operative setting.  
The focus of the most recent genetic studies was on the effect of a single gene on pain 
sensitivity and response to opioid (Fernandez-de-las-Penas et al., 2012; Henker et al., 2013; 
Kambur et al., 2013). Though, the combination or interaction of multiple pain genes may be 
responsible for better understanding and a sturdier explanation of patient’s variability in pain 
response. The gene–gene interaction effect of OPRM1 and COMT on pain and opioid response is 
not well understood. Thus, more studies are needed to establish the impact of this relationship on 
response to pain management. We expanded COMT analyses from single SNP to haplotype 
analyses to warrant more detailed data and a better understanding of COMT variability in pain 
(Diatchenko et al., 2006; Diatchenko et al., 2005; Nackley et al., 2006; Rakvag et al., 2008), our 
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proposed study was innovative since it was the first to consider COMT haplotypes as well as 
COMT Val158Met SNP interaction with OPRM1 A118G which provides a better understanding 
of the inter-individual variability of pain and responses to opioids rather than the effects of SNPs 
alone.  
Our study had a relatively larger sample size and more uniform type of surgical operation 
as single orthopedic procedures, addressing certain limitations of previous work (Kolesnikov et 
al., 2011). Evidence shows that patients undergoing orthopedic surgical procedures experience 
moderate to severe pain (Chung, Ritchie, & Su, 1997; Morin et al., 2005); supported by the fact 
that bone injury is more painful than soft tissue injury (Chung et al., 1997). Thus, our population 
was ideal for investigating postoperative pain and patient response to opioids. 
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3.0  METHODS 
3.1 RESEARCH DESIGN 
This descriptive observational study used previously obtained genotyping data of a parent study 
that prospectively enrolled a convenience sample of 153 patients between 2005 and 2009. The 
previous study examined the independent effects of OPRM1 and COMT genotypes on 
postoperative pain, opioid use, and opioid-induced sedation (Henker et al., 2013). The parent 
study had 79 patients while the proposed study included an additional 74 patients. Recruitment 
and data on demographic and other clinical characteristics from these additional patients were 
collected using the same procedures as the initial 79 patients. 
3.2 CLINICAL SETTING OF THE PARENT STUDY 
The University of Pittsburgh Medical Center (UPMC)-Presbyterian University Hospital (PUH) is 
an 816 bed hospital designated as a Level I Regional Trauma Center fully accredited by the 
Pennsylvania Trauma Systems Foundation.  UPMC-PUH has 43 operating rooms and 2 post 
anesthesia care units (PACU). 
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3.3 SAMPLE 
Saliva samples were available for analysis from 153 postoperative orthopedic trauma patients. 
Inclusion criteria of the parent study (that will also be used for the proposed study) were  1) 18 to 
80 years of age; 2) opioid-naïve; 3) received general or general and regional anesthesia; 4) single 
orthopedic procedure; and 5) planned surgical time of 1 to 4 hours in length.  
Exclusion criteria were 1) second orthopedic trauma site; 2) abdominal or thoracic 
trauma; 3) history of mental illness (e.g., depression, bipolar disorder, schizophrenia); 4) 
currently taking phenothiazines; 5) history of hepatic disease (e.g., history of hepatitis C); 6) 
history of renal disease; 7) American Society of Anesthesiologist Physical Status >3; 8) previous 
history or neurologic conditions such as stroke, head injury, spinal cord injury, intracerebral 
hemorrhage; and 9) previous history of arthritis or bone disease. 
3.3.1 Justification of the Sample Size 
Testing interaction effects generally requires a much larger sample size than testing for main 
effect of single SNP or haplotype. As such, our study is an exploratory, rather than a 
confirmatory study of the putative interaction effects of COMT and OPRM1 using data collected 
from 153 patients enrolled to date. A formal sample size calculation was not performed; 
however, the effect sizes estimated from our study will be informative for estimating the sample 
size for a large scale genomic study in the same patient population. 
 38 
3.4 RECRUITMENT 
Subjects were recruited as part of the parent study. Once patient eligibility was confirmed, the 
study was explained in detail including the study purpose, risks, benefits, and data collection 
procedure by the study personnel. If the patient was willing to participate, informed consent was 
obtained. 
3.5 DATA COLLECTION 
Investigators with clinical privileges at UPMC-PUH identified patients scheduled to receive 
general anesthesia for a single orthopedic surgical procedure with an anticipated duration of 1 to 
4 hours. Once eligibility was confirmed, the patient was approached and the study explained in 
detail. If the patient was willing to participate, informed consent was obtained in the preoperative 
holding area or the patient’s hospital room. Once enrolled, subjects were taught how to use the 
Numerical Pain Scale (NPS); the NPS was recorded prior to entering the Operation Room (OR) 
and then at 45 minutes after PACU admission by study personnel. The total amount of opioids 
used during PACU stay was recorded by study personnel. Demographic data (including gender, 
race, ethnicity, age, weight, smoking, anatomic site of repair, length of surgical time, length of 
operating room time and PACU time) were extracted from the medical record. Saliva was 
collected the first day after surgery (subjects have difficulty providing saliva prior to surgery due 
to being NPO for 8 hours prior to surgery) and stored at room temperature and evaluated for 
genotype. 
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3.6 STUDY VARIABLES 
Pain score and opioid use in the immediate postoperative period were treated as dependent 
variables. OPRM1 A118G (rs1799971) SNP and COMT SNPs (rs6269, rs4633, rs4818 and 
rs4680) haplotypes and diplotypes were treated as the main independent variables of interest, 
with selected patient demographics and baseline clinical characteristics as covariates. 
3.6.1 Opioid consumption  
Opioid consumption was the amount of opioids per kg received by subjects in the OR and 
PACU. Time and amount of opioids administered during PACU were abstracted from the PACU 
record. The amount of opioid administered was converted to morphine equivalents as follows: 
100 µg fentanyl was converted to 10 mg of morphine, 1.5 mg hydromorphone was converted to 
10 mg of morphine, and 75 mg of meperidine was converted to 10mg of morphine. Opioid dose 
was analyzed as a continuous dependent variable for the first aim. 
3.6.2 Pain response 
Pain was assessed using the numeric pain scale (NPS), an 11-point verbal pain response scale 
from 0 (“no pain”) to 10 (“pain as bad as I can imagine”). Pain scores were collected in the 
preoperative holding area and within 45 minutes after arrival in the PACU.  Pain was analyzed as 
a continuous dependent variable for the second aim.   
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3.6.3 Genetic data 
Oragene DNA self-collection kit from DNA Genotek Incorporated (Ottawa, Ontario, Canada) 
was used to collect saliva samples from subjects. DNA was extracted from saliva samples 
applying the protocol and reagents for extraction supplied with the Oragene kit. The extracted 
DNA was stored and then used to evaluate genotypes. 
3.6.3.1 OPRM1 A118G 
OPRM1 A118G (rs1799971) was genotyped using sequencing. The forward primer (50-
TCAGTACCATGGACAGCAG-30) and reverse primer (50-GGAGTAGAGGGCCATGAT-30) 
were used in a polymerase chain reaction (PCR) with an annealing temperature of 59 °C. The 
PCR products were cleaned with ExoSAP reagents (USBiochemicals, Cleveland, OH). Then, the 
sequencing was performed using the reverse primer and Big Dye Cycle Sequencing reagents 
(Applied Biosystems, ABI, Foster City, CA). The sequencing products were electrophoresed 
using ABI377 automated sequencer (ABI). Finally, the data were viewed and genotypes were 
assigned using Sequencer software (Gene Codes Corporation, Ann Arbor, MI). Only two 
patients (1.3%) were homozygous for the G variant. Thus, we combined heterozygous and 
homozygous for the G variant into one group. OPRM1 A118G was coded as having two levels 
(‘no minor allele G’ and ‘1 or 2 minor allele G’) and was treated as a nominal independent 
variable for both aims. 
3.6.3.2 COMT  
The four COMT SNPs including rs6269, rs4633, rs4818, and rs4680 were genotyped using 5' 
exonuclease Assay-on-Demand TaqMan assays (ABI). Amplification and genotype assignments 
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were next conducted using the ABI7000 and SDS 2.0 software (ABI). COMT SNPs were treated 
as independent variable for both aims. COMT haplotypes, constructed by four COMT SNPs; 
rs6269, rs4633, rs4818 and rs4680, were designated as low pain sensitivity (LPS; GCGG), 
average pain sensitivity (APS; ATCA) and high pain sensitivity (HPS; ACCG) (Diatchenko et 
al., 2005). Using combinations of the three major haplotypes, we created two major diplotypes; 
low pain sensitivity diplotype (two copies of LPS haplotype or one copy each of LPS/APS 
haplotypes) and high pain sensitivity diplotype (two copies of APS haplotype, two copies of HPS 
haplotype, one copy each of LPS/HPS haplotypes, one copy each of APS/HPS haplotypes). Each 
of COMT haplotypes has three levels; having no copies, having one copy and having two copies 
of the haplotype. Since we did not have enough patients in those three levels, we combined 
patients having one copy of the haplotype and patients having two copies of the haplotype into 
one group as “having at least one copy of the haplotype”. Thus, COMT haplotypes were coded 
into two levels (‘having no copies’ and ‘having at least one copy’). COMT haplotypes and 
diplotypes were also treated as independent variables for both aims. 
3.6.4 Demographic and clinical characteristics 
Gender (2 levels; male and female), race (2 levels; Caucasian and other), smoking status (2 
levels; smoker and non-smoker), fracture types (5 levels; ankle, tibia/fibula, tibial plateau, femur 
and other), and preoperative pain (2 levels; no/mild pain and moderate/severe pain) were treated 
as nominal variables. Age (measured in years) and OR opioid (measured in mg/kg/hr) were 
treated as continuous variables. All data were collected from the patient and medical records, and 
their effects were adjusted as possible covariates in our association analyses.  
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3.7 ANALYSIS PLAN 
3.7.1 Genotype quality control 
To ensure accuracy of association results, we assessed the quality of the genotyping data using 
filters on call rate (CR) (>0.95), repeatability of calls (>0.99), and checks comparing expected 
homozygosity to observed homozygosity at each marker. We assessed Hardy–Weinberg 
equilibrium (HWE) for all genotyped SNPs using Fisher's exact test implemented in the software 
PLINK (Purcell et al., 2007), which was also used to estimate the allele frequencies of SNPs as 
well as the frequencies of COMT haplotypes and diplotypes. The Haploview software 
(http://www.broad.mit.edu/mpg/haploview) was used to visualize the pairwise linkage 
disequilibrium (LD) between the selected four COMT SNPs measured by Lewontin’s D' (Barrett, 
Fry, Maller, & Daly, 2005). 
3.7.2 Data screening procedures 
Data analyses were performed using IBM® SPSS® Statistics (Version 22, IBM Corp., Armonk, 
NY). Assessment of data accuracy was performed prior to the main data analysis using 
descriptive statistics and graphical plots to ensure the valid analysis of data. The amounts and 
patterns of missing data were reviewed. For each variable in our model, a variable missing value 
indicator (missing=1, observed=0) was created, then t-tests or chi-square tests were conducted 
between each of these indicator variables and the observed values of the other variables in the 
model. Missing observations were assumed to be missing completely at random. Most missing 
data were genetic information for OPRM1 or COMT or both. Cases with missing genetic data 
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(n=28, 18%) or missing postoperative pain score (n=2, 1.3%) or opioid dose (n=2, 1.3%) were 
excluded from the analysis.  
Univariate outliers were reviewed carefully and verified against the research records. 
Score alteration was applied for outliers of opioid consumption during PACU and opioid 
consumption in the OR, setting outliers or extreme values closer to the remaining cases while 
keeping the relative ordering (Tabachnick, 2013). Multivariate outliers and potentially influential 
observations (based on studentized deleted residuals and leverage values) were further evaluated 
using, Cook’s D, |DFFITS| and |DFBETAS| during model assessment. 
3.7.3 Data analysis for specific aims 
All statistical analyses to address study aims were preceded by detailed descriptive analyses of 
the data, using standard descriptive summaries (e.g., means, standard deviations, median, 
minimum, maximum, percentiles, ranges) and graphical techniques (e.g., histograms and 
scatterplots) for all continuous variables including pain scores, opioid doses, and age. 
Frequencies and percentages were examined for categorical variables including OPRM1, COMT, 
gender, race, smoking, preoperative pain and fracture types. No adjustment to significance level 
was made for multiple testing, since the purpose of this study was more exploratory than 
confirmatory of the putative interaction effects of COMT and OPRM1. 
Since haplotype structure may vary by race, we conducted a subgroup analysis limited to 
only Caucasian subjects (n=121; 79%). Though our sample size decreased, we were interested in 
exploring the magnitude and direction of the estimated regression coefficients for a 
homogeneous sample of Caucasians. Sample sizes for other ethnicities were too small to conduct 
subgroup analyses. 
 44 
3.7.3.1 Specific aim #1 
To explore the gene-gene interaction effect of OPRM1 and COMT on opioid dose required 
for pain management during PACU stay. 
First, descriptive statistics as well as graphical plots were created to describe the distribution of 
postoperative opioid dose in PACU stay among COMT SNPs (rs6269, rs4633, rs4818 and 
rs4680), haplotypes and diplotypes and among their combined groups with OPRM1 A118G. 
Opioid distribution patterns among OPRM1 levels were also described.  Hierarchical multiple 
regression analysis modeling was applied considering each of COMT SNPs (including the 
additive, dominant and recessive effects), haplotypes and diplotypes with A118G SNP to 
investigate their individual and interactive effects on PACU opioid consumption after adjustment 
identified covariates including gender, race, age, smoking, fracture type and OR opioid 
consumption. The significance of the interaction terms and their regression coefficients with 
confidence intervals were reported as well as the proportion of the variance accounted by each 
interaction term. 
Any violations of assumptions underlying the planned methods of analysis were assessed 
including non-normality of model errors and heterogeneity of error variance and serious 
multicollinearity. Histogram of the studentized deleted residuals and P-P plot of studentized 
deleted residuals against the predicted values were examined for any deviation from normality. 
The assumption of normality was met for postoperative opioid consumption in the PACU. The 
Levene's test was also used to examine the homogeneity of group variances. The variance 
inflation factors (VIF) and tolerance values were examined to screen for multicollinearity. The 
assumption of homogeneity of the variance was also met and no serious multicollinearity was 
found. 
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3.7.3.2 Specific aim #2 
To explore the gene-gene interaction effect of OPRM1 and COMT on postoperative pain 
score at 45 minutes in PACU. 
Descriptive statistics as well as graphical plots were used to characterize the distribution of 
postoperative pain among COMT SNPs (rs6269, rs4633, rs4818 and rs4680), haplotypes (LPS, 
APS, and HPS), and diplotypes (low pain intensity and high pain intensity) and among their 
combinations with OPRM1 A118G. Pain distribution patterns among OPRM1 levels was also 
described.  Hierarchical multiple linear regression was used, where each of the COMT SNPs 
(including the additive, dominant and recessive effects), haplotypes and diplotypes was included 
in the regression model with A118G SNP to investigate their individual and interactive effects on 
pain score at 45 minutes in the PACU after adjustment for the associated covariates including 
gender, race, age, smoking, fracture type, preoperative pain, OR opioid consumption and opioid 
consumption during the first 45 minutes in PACU. The significance of the interaction terms and 
their regression coefficients with confidence intervals were reported as well as the proportion of 
the variance accounted by each interaction term.   
Any violations of assumptions underlying the planned methods of analysis were checked, 
including non-normality of model errors and heterogeneity of error variance and serious 
multicollinearity. Histogram of the studentized deleted residuals and P-P plot of studentized 
deleted residuals against the predicted values were examined for any deviation from normality. 
The assumption of normality of model errors was not met for postoperative pain at 45 minutes in 
PACU (severely negatively skewed residuals). Data transformations (square root transformation 
of reflected values of postoperative pain at 45 minutes in the PACU) were used to remediate the 
violation of normality assumption. The Levene's test was used to examine the homogeneity of 
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group variances. The variance inflation factors (VIF) and tolerance values were examined to 
screen for multicollinearity.  The assumption of homogeneity of the error variance was satisfied 
and no severe multicollinearity was found. 
3.8 LIMITATIONS 
While our proposed sample size is larger than what is reported in the literature in the area of pain 
(Kolesnikov et al., 2011), it is still relatively small for a general genetic study of a common 
disease or phenotype. Because of the small sample size, the homozygous and heterozygous G 
variants for A118G were combined into one group as ‘having 1 or 2 G alleles’. We also 
combined subjects having one copy and two copies of each of COMT haplotype into one group 
as “having at least one copy of the haplotype”. 
There are also limitations of using data that were collected previously as we were not 
able to consider other pain-related factors that may contribute to the variability in pain and 
response to opioids such as expected pain, surgical fear, and pain catastrophizing. Moreover, 
mixing different types of opioids in the analysis may affect our final findings; different types of 
opioid display different pharmacological properties as they bind with different affinity to opioid 
receptors.  
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3.9 HUMAN SUBJECTS 
This secondary analysis will use data collected for the parent study (NIH 1 UL1 RR024153) that 
was approved by the Institutional Review Board (IRB) at the University of Pittsburgh. The risk 
in the proposed study is minimal and is limited to potential loss of confidentiality related to 
disclosure of genetic information. The risk of confidentiality was minimized by assignment of a 
unique identification number rather than personal identifiers for all the subjects. All data files 
were maintained in a locked office in a locked department in the School of Nursing.  Electronic 
data were stored on password protected computers. No exclusion of potential participants was 
made based on gender, ethnicity or race. 
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4.0  SUMMARY OF STUDY 
4.1 RESULTS  
4.1.1 Demographic and clinical characteristics 
One hundred and fifty-three postoperative patients with average (±SD) age of 38.48 ±13.1 years 
that underwent surgical orthopedic trauma repair were included in the study. Most (68%) of the 
sample was male (n=104), 80% (n=121) were non-Hispanic Caucasian, and 57 % (n=86) were 
nonsmokers. 
Thirty-nine percent (n=56) of the patients were admitted with ankle fractures, 24% 
(n=35) with tibia fibula fractures, 21% (n=30) with tibial plateau fractures, 11% (n=16) with 
femur fractures, and 5% (n=7) with other types of fractures including; radial, ulnar, humerus, 
acetabular and hip. The average (±SD) of preoperative pain score was 4.53 ± 2.92. The average 
(±SD) surgical time was 119.96 ± 59.51 minutes. OR opioid consumption ranged from 0 to 1.35 
mg/kg with an average (±SD) of 0.42 ± 0.22. The average postoperative pain scores at 15 and 45 
minutes of PACU admission were 6.59 ± 3.2 and 6.42 ± 2.79, respectively. Total opioid 
consumption during PACU stay ranged from 0 to 0.36 mg/kg with an average (±SD) of 0.11 ± 
0.09 mg/kg. The average (±SD) of PACU stay was 128.99 ± 56.40 minutes. Descriptive statistics 
by OPRM1 A118G and COMT SNPs, haplotypes and diplotypes are presented in Table 3. 
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Table 3. Descriptive statistics by OPRM1 A118G and COMT SNPs, haplotypes and diplotypes 
 n Gender 
(Male) 
Race 
(Caucasian) 
Age 
(Years) 
Preoperative 
Pain 
Postoperative 
Pain in 
PACU 
(at 45 min) 
OR 
Opioid 
(mg/kg/hr) 
PACU 
Opioid 
(mg/kg) 
A118G(Dominant)         
AA 95 70 (71) 77 (79) 39.8±13.4 4.6±2.9 6.4±2.9 .24±.14 .10±.08 
AG,GG 
 
27 16 (57) 22 (79) 36.5±14.3 4.2±3.0 6.5±2.7 .26±.14 .16±.11 
RS4680(Recessive)         
AA 32 20 (63) 30(94) 37.4±13.0 4.5±2.8 7.1±2.6 .25±.13 .13±.08 
AG,GG 
 
90 66 (70) 69(73) 39.7±13.8 4.5±2.9 6.2±2.9 .24±.14 .11±.09 
RS6269(Recessive)         
AA 38 25(66) 34(90) 37.4±12.9 4.3±2.7 7.1±2.6 .25±.13 .12±.08 
GA,GG 
 
79 56(68) 61(74) 40.4±13.9 4.6±2.9 6.0±2.9 .24±.14 .11±.10 
RS4633(Recessive)         
TT 30 20(67) 28(93) 38.3±13.2 4.3±2.8 7.3±2.7 .24±.13 .13±.09 
CT,CC 
 
89 64(69) 68(73) 39.9±13.7 4.5±3.0 6.2±2.8 .24±.14 .11±.09 
RS4818(Dominant)         
CC 42 29(69) 33(79) 36.3±11.6 4.3±3.1 7.3±2.6 .27±.14 .12±.08 
GG,GC 
 
76 55(69) 63(79) 40.8±14.2 4.5±2.8 6.1±2.9 .23±.14 .12±.10 
LPS Haplotype         
0 copy 48 30(63) 38(79) 37.5±13.2 4.6±3.1 7.0±2.6 .26±.14 .12±.08 
1 or 2 copies 
 
74 56(72) 61(78) 40.1±13.9 4.4±2.8 6.1±2.9 .23±.14 .11±.10 
APS Haplotype         
0 copy 54 38(66) 42(72) 41.1±14.0 5.3±3.0 6.2±3.0 .25±.15 .11±.09 
1 or 2 copies 
 
68 48(71) 57(84) 37.5±13.1 3.8±2.6 6.6±2.7 .24±.13 .12±.09 
HPS Haplotype         
0 copy 99 73(71) 86(84) 39.9±13.7 4.2±2.7 6.4±2.8 .24±.14 .12±.10 
1 or 2 copies 
 
23 13(57) 13(57) 35.7±12.7 5.6±3.4 6.4±3.0 .27±.15 .10±.07 
Diplotype         
Low 69 53(73) 58(80) 41.5±14.1 4.2±2.7 6.1±2.8 .23±.14 .11±.10 
High 53 33(62) 41(77) 35.9±12.4 4.8±3.1 6.9±2.8 .26±.14 .12±.08 
Descriptive statistics reported in cell are expressed as mean±SD for continuous variables and n (%) for categorical variables. 
LPS= Low pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain Sensitivity; PACU = postanesthesia care unit; 
OR= Operation Room. 
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4.1.2 Genetic characteristics 
One SNP from OPRM1 (rs1799971) and four SNPs from COMT (rs4680, rs4633, rs4818, and 
rs6269) were included in the analysis. Genotype and allele frequencies of OPRM1 and COMT 
SNPs are presented in Table 2. For OPRM1 A118G; there were 106 (78%) patients that had no 
minor allele G (AA) and 30 (22%) that had 1 or 2 minor alleles G (AG and GG). For COMT 
rs4680; 37 (27%) had Met158Met (AA), 46 (34%) had Met158Val (AG), and 53 (39%) had 
Val158Val (GG). For COMT rs6269; 40 (31%) had AA, 49 (37%) had GA, and 42 (32%) had 
GG. For COMT rs4633; 52 (39%) had CC, 48 (36%) had CT, and 33 (25%) had TT. For COMT 
rs4818; 30 (23%) had GG, 56 (43%) GC, and 45 (34%) CC. 
Three of the four COMT SNPs (rs4680, rs4633, and rs6269) displayed significant 
deviation from HWE and corresponding p-values are shown in Table 4. COMT SNPs were out of 
equilibrium even after restricting our analyses to Caucasian subjects. Systematic lab review of 
raw genotype data was performed to exclude that deviations from HWE were due to genotyping 
error. It is possible that deviations from HWE in COMT SNPs as a result of the small size of our 
sample. Another possible explanation is that deviation from HWE is due to the distinctive 
characteristics of our sample. Thus, our sample may not be completely representative of the 
general population. Despite violations of HWE, COMT SNPs are genetically related; they 
collectively influence the biological process of pain. Furthermore, pairwise linkage 
disequilibrium values computed by Haploview software showed that all COMT SNPs rs4680, 
rs4633, rs4818 and rs6269 were in strong LD (D' > 0.75) (Figure 6). 
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Table 4. Genotype and allele frequency of OPRM1 and COMT SNPs 
Allelesa Genotypes 
Gene SNP Chromosome Position A1 A2 MAFb A1/A1 A1/A2 A2/A2 HWEc
OPRM1 rs1799971 6 154360797 G A 0.1176 2 28 106 1 
COMT rs4680 22 19951271 A G 0.4412 37 46 53 0.00025 
rs4633 22 19950235 T C 0.4286 33 48 52 0.00258 
rs4818 22 19951207 G C 0.4427 30 56 45 0.15560 
rs6269 22 19949952 A G 0.4924 40 49 42 0.00494 
aA1: Minor allele; A2: Major allele; bMAF: Minor Allelic Frequency; c(HWE) : Hardy-Weinberg Equilibrium test p-
value. 
The distribution of COMT haplotypes and diplotypes were as follow; 52(39%) patients 
had no copies of LPS haplotype and 82(61%) had at least one copy; 63(47%) patients had no 
copies of APS haplotype and 71(53%) had at least one copy; 110(82%) patients had no copies of 
HPS haplotype and 24(18%) had at least one copy. Regarding COMT diplotypes; 77(57%) 
patients had low pain sensitivity diplotype and 57(43%) had high pain sensitivity diplotype 
(Figure 6). 
Figure 6. Linkage disequilibrium (LD) graph of COMT SNPs 
Linkage disequilibrium (LD) graph of COMT SNPs “left” and Haplotype frequency “right”. LD was calculated using D' (0= no disequilibrium; 1= maximum 
disequilibrium). The numbers inside the squares are 100 × D'. Graph was created using Haploview software. LPS= Low pain Sensitivity; APS= Average 
pain Sensitivity; HPS= High pain Sensitivity 
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4.1.3 OPRM1 × COMT effect on postoperative pain and opioid consumption 
One hundred and fifty-three patients were available for our data analysis. A hierarchical multiple 
regression was performed using postoperative pain score at 45 minutes in PACU and opioids 
consumption during PACU stay as the dependent variables. OPRM1 A118G (under dominant 
genetic model), the four COMT SNPs including rs6269, rs4633, rs4818 and rs4680 (under 
additive, dominant, and recessive genetic models), the three COMT haplotypes (low, average, 
and high pain sensitivity), and COMT diplotypes (low and high pain sensitivity) as independent 
variables. Main and interaction effects of the independent variables were investigated after 
adjustment for the associated covariates. Correlations between OPRM1 and COMT and variables 
of interest are presented in Table 5. Correlations between pain and opioid variables and other 
variables of interest are presented in Table 6. 
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Table 5. Spearman's rank correlation coefficient (rs) between OPRM1, COMT, dependent variables and 
covariates  
 A118G rs4680 rs4633 rs4818 rs6269 LPS APS HPS Diplotype 
Male Gender .128 -.083 -.054 .066 .015 -.10 -.05 .119 .110 
Caucasian Race <.001 .159 -.063 .242** .207* .011 -.14 .254** .025 
Age (years) -.098 -.014 -.081 -.079 -.179* .082 -.11 -.113 -.189* 
None smoker -.146 -.083 -.106 -.108 .001 .006 -.02 -.070 -.010 
Ankle Fracture Type -.049 -.016 .017 -.120 -.048 -.05 .058 -.104 -.016 
Surgical Time 
(minutes) 
.096 .014 .103 -.061 -.043 .065 .058 -.146 -.115 
Preoperative Pain 
Score 
-.069 -.091 -.195* .008 -.166 -.02 -.3** .170 .084 
Pain 45 minutes in 
PACU 
.015 -.102 -.012 -.009 .054 -.16 .082 .002 .143 
OR Opioid (mg/kg) .217* -.082 -.033 -.148 -.041 -.04 -.00 -.092 -.023 
PACU Opioid 
(mg/kg) 
.258** -.028 .114 .105 .090 -.06 .116 -.056 .044 
PACU Time 
(minutes) 
.113 .060 .122 .166 .207* -.07 .088 .101 .030 
* p<.05, ** p<.001, LPS= Low Pain Sensitivity; APS= Average Pain Sensitivity; HPS= High Pain Sensitivity; 
PACU = Post Anesthesia Care Unit; OR= Operation Room. 
 
Table 6. Spearman's rank correlation coefficient (rs) between pain, opioid, and covariates 
 Preoperative 
Pain Score 
Postoperative Pain Score in 
PACU 
OR Opioid  PACU Opioid  
Preoperative Pain Score -- .137 .139 .085 
Pain 15 minutes in 
PACU 
-.023 .433** .328** .386** 
Pain 45 minutes in 
PACU 
.137 -- .173 .400** 
OR Opioid (mg/kg) .139 .173 -- .203** 
PACU Opioid (mg/kg) .085 .400** .203* -- 
Male Gender .050 -.030 .037 .065 
Caucasian Race .056 .130 .081 -.099 
Age (years) .009 -.104 -.210* -.123 
None smoker .179* .079 .130 -.069 
Ankle Fracture Type .105 .260** .129 .137 
Surgical Time (minutes) .018 -.067 .259** -.069 
PACU Time (min) .176 .106 .010 .015 
* p<.05, ** p<.001; PACU = postanesthesia care unit; OR= Operation Room. 
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4.1.4 OPRM1 × COMT effect on opioid consumption 
Regression analysis results for predicting PACU opioid consumption by OPRM1 × COMT are 
summarized in Table 7. In addition to the main effects of both OPRM1 and COMT, the 
interaction analysis controlled for gender, race, age, smoking, fracture type and OR opioid 
consumption. Figure 7 displays the interaction effects of OPRM1 × COMT on PACU opioid 
consumption for the typical subject in our sample; Caucasian, male, with ankle fracture, a mean 
age of 38.9 years, and a mean OR opioid consumption of 0.246 mg/kg/hr. 
 
Table 7. Regression analysis summary for predicting PACU opioid (mg/kg) by OPRM1× COMT (Total 
sample) 
Interaction Variable n b 95%CI Beta p-value  sr2 
 
OPRM1 A118G×COMT rs4680 
(Recessive) 
 
 
123 
 
0.093 
 
(0.006,0.179) 
 
0.235 
 
.037 
  
.031 
OPRM1 A118G×COMT rs4633 
(Recessive) 
 
120 0.097 (0.006,0.189 ) 0.231 .037  .033 
OPRM1 A118G×COMT rs4818 
(Dominant) 
 
119 -0.044 (-0.126,0.037) -0.170 .284  .009 
OPRM1 A118G×COMT rs6269 
(Recessive) 
 
118 -0.075 (-0.160,0.010) -0.305 .082  .023 
OPRM1 A118G×COMT LPS 
Haplotype 
 
123 -0.047 (-0.125,0.030) 0.174 .230  .011 
OPRM1 A118G×COMT APS 
Haplotype 
 
123 0.009 (-0.068,0.086) 0.034 .818  <.001 
OPRM1 A118G×COMT HPS 
Haplotype 
 
123 0.001 (-0.095,0.098) 0.003 .982  . <.001 
OPRM1 A118G×COMT  
Diplotypes 
123 0.071 (-0.006,0.148) 0.231 .070  .024 
Interaction analysis controlled for the main effects of both OPRM1 and COMT, gender, race, age, smoking, fracture 
type and OR opioid consumption. LPS= Low pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain 
Sensitivity 
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Figure 7. The interaction effects of OPRM1× COMT (SNPs, haplotypes, and diplotypes) on PACU 
opioid for the total sample 
The displayed graphs are for the typical subject in our sample in terms of the covariates; Caucasian, male, with ankle 
fracture, a mean age of 38.9 years, and a mean OR opioid consumption of 0.246mg/kg/hr. , LPS= Low Pain Sensitivity; 
APS= Average Pain Sensitivity; HPS= High Pain Sensitivity. 
56 
One multivariate outlier and possibly influential point was identified in PACU opioid 
consumption analyses. Case 25 has high values of studentized deleted residuals, leverage, Cook's 
D, |DFFITS| and |DFBETAS|. This case represents a 23 year old Caucasian male subject with 
radial fracture. This subject had the largest total opioid consumption during PACU stay (total 
PACU opioid dose = 40 mg; .36mg/kg).  Of a maximum verbal pain rating of 10, his pain score 
before surgery was 9. His postoperative pain ratings at 15 and 45 minutes in PACU were 10. The 
genetic characteristics of this subject were AG for OPRM1 A118G, GA for COMTrs6269, CT 
for COMTrs4633, GC for COMTrs4818, AG for COMTrs4680, one copy of each of LPS and 
APS, and low pain sensitivity diplotype. A sensitivity analysis was conducted to investigate the 
influence of this outlier on regression model results. Sensitivity analysis showed the findings (in 
terms estimated regression coefficients and standard errors) were robust to the exclusion of case 
25 as findings were not changed when case 25 was excluded (Table 8). 
Table 8. Regression results for the OPRM1 × COMT interaction for PACU opioid (mg/kg) with inclusion (*) 
and exclusion (**) of case #25 
Interaction Term b* b** %Δb SE* SE** % ΔSE p* p** 
OPRM1 A118G×COMT rs4680 .093 .098 5.4 .044 .043 2.3 .037 .024 
OPRM1 A118G×COMT rs4633 .097 .103 6.2 .046 .045 2.2 .037 .023 
OPRM1 A118G×COMT rs4818 -.044 -.051 16.0 .041 .040 2.4 .284 .208 
OPRM1 A118G×COMT rs6269 -.075 -.081 8.0 .043 .042 2.3 .082 .055 
OPRM1 A118G×COMT LPS 
Haplotype 
-.047 -.056 19.1 .039 .038 2.3 .230 .150 
OPRM1 A118G×COMT APS 
Haplotype 
. 009 -.006 166.67 .039 .039 0 .818 .878 
OPRM1 A118G×COMT HPS 
Haplotype 
.001 .013 1200 .049 .048 2.3 .982 .786 
OPRM1 A118G×COMT Diplotype .071 .083 16.9 .039 .038 2.3 .070 .032 
LPS= Low Pain Sensitivity; APS= Average Pain Sensitivity; HPS= High Pain Sensitivity. 
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A significant interaction was found between COMT Val158Met (rs4680) assuming a 
recessive genetic model (Met158Met vs Val158Met/Val158Val) and OPRM1 A118G assuming a 
dominant genetic model (A118G/G118G vs A118A), b = 0.093, p < .05. The effect of OPRM1 
on opioid consumption is varied for the different genotypes of COMT Val158Met. Considering 
Met158Met of COMT, there was a significant increase in opioid consumption as we move from 
OPRM1 wild type (AA) to variants (AG/GG). Patients having Met158Met (AA) of COMTrs4680 
and (AG/GG) of OPRM1A118G consumed more opioids compared to patients having 
Met158Met (AA) of COMTrs4680 and AA of OPRM1A118G, 95% CI = [0.006, 0.179]. 
OPRM1A118G × COMTrs4680 accounted uniquely for 3.1% of the total PACU opioid 
consumption variance. 
A significant interaction was also found between COMTrs4633 assuming a recessive 
genetic model (TT vs. CT/CC) and OPRM1 A118G assuming a dominant genetic model 
(AG/GG vs. AA), b = 0.097, p < .05. Considering TT of COMT rs4633, there was a significant 
increase in opioid consumption as we move from OPRM1 wild type (AA) to variants (AG/GG). 
Patients having TT of COMTrs4633 and (AG/GG) of OPRM1A118G consumed more opioids 
compared to patients having TT of COMTrs4633 and AA of OPRM1A118G, 95% CI = [0.006, 
0.189]. OPRM1A118G × COMTrs4633 accounted uniquely for 3.3% of the total PACU opioid 
consumption variance. 
No significant interactions were found between OPRM1 and the COMT SNPs of rs6269 
and rs4818. However, the interaction of COMT rs6269 assuming a recessive genetic model and 
OPRM1 assuming dominant genetic model demonstrated a trend (p = .08). Patients having AA of 
COMTrs6269 and AG/GG of OPRM1A118G consumed more opioids compared to patients 
having AA of COMTrs6269 and AA of OPRM1A118G, b=-0.075, 95% CI = [-0.16, 0.01].  
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No significant interaction was found between OPRM1 and COMT haplotypes or 
diplotypes. However, the interaction of COMT diplotype and OPRM1 assuming a dominant 
genetic model demonstrated a trend towards significance (p = .07). Patients having high pain 
sensitivity diplotype and (AG/GG) of OPRM1A118G consumed more opioids compared to 
patients having high pain sensitivity diplotype and AA of OPRM1A118G, b = 0.071 95% CI = [-
0.006, 0.148]. 
OPRM1 A118G assuming a dominant genetic model was significantly associated with 
opioid consumption during PACU stay, b = 0.046, p < .05, sr2 = .04. Patients having one or two 
minor alleles G (AG and GG) consumed significantly 0.046 mg/Kg more opioids during PACU 
stay compared to patients having AA, 95% CI = [0.008, 0.085].  
Restricting our analysis to Caucasian subjects did not change the statistical significance 
for the interaction effects of both OPRM1A118G × COMT rs4680 and OPRM1A118G × COMT 
rs4633 on PACU opioid consumption (Table 9). Figure 8 shows the interaction effect of OPRM1 
× COMT on PACU opioid consumption for Caucasian subjects who were male, with ankle 
fracture, with a mean age of 39.9 years, and a mean OR opioid consumption of 0.233 mg/kg/hr. 
Restricting our analysis to Caucasian subjects changed the direction of the regression coefficient 
for the interaction effect of OPRM1A118G × APS and OPRM1A118G × HPS haplotypes. 
However, changes were small and not statistically significant. Table 10 represents the changes in 
regression statistics for PACU opioid (mg/kg) when the analysis is restricted to Caucasian 
subjects. 
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Table 9. Regression analysis summary for predicting PACU opioid (mg/kg) by OPRM1× COMT (Caucasian 
only sample) 
Interaction Variable n b 95%CI Beta p-value sr2 
 
OPRM1 A118G×COMT rs4680 
(Recessive) 
 
 
96 
 
0.108 
 
(0.017,0.200) 
 
0.300 
 
.021 
 
.047 
OPRM1 A118G×COMT rs4633 
(Recessive) 
 
93 0.102 (0.006,0.199) 0.264 .038 .039 
OPRM1 A118G×COMT rs4818 
(Dominant) 
 
93 -0.058 (-0.153,0.036) -0.217 .223 .014 
OPRM1 A118G×COMT rs6269 
(Recessive) 
 
92 -0.070 (-0.163,0.023) -0.264 .136 .021 
OPRM1 A118G×COMT LPS 
Haplotype 
 
96 -0.059 (-0.149,0.031) -0.208 . 194 .015 
OPRM1 A118G×COMT APS 
Haplotype 
 
96 -0.015 (-0.1060,.077) -0.057 . 750 .<.001 
OPRM1 A118G×COMT HPS 
Haplotype 
 
96 -0.073 (-0.191,0.045) -0.155 .222 .013 
OPRM1 A118G×COMT  Diplotypes                       96 0.047 (-0.040,0.135) 0.154 .285 .010 
Interaction analysis controlled for the main effects of both OPRM1 and COMT, gender, age, smoking, fracture type 
and OR opioid consumption. LPS= Low pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain 
Sensitivity 
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Figure 8. The interaction effect of OPRM1× COMT (SNPs, haplotypes, and diplotypes) on PACU 
opioid using Caucasian sample
Graphs display the OPRM1 × COMT interaction effects for the typical Caucasian subject in our sample; 
male, with ankle fracture, a mean age of 39.9 years, and a mean OR opioid consumption of 0.233mg/kg/hr. , 
LPS= Low Pain Sensitivity; APS= Average Pain Sensitivity; HPS= High Pain Sensitivity. 
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Table 10. Changes and percentage changes in PACU opioid regression statistics when the sample is restricted 
to Caucasians 
Interaction Variable bT* bC** %*** SET SEC % pT pC 
OPRM1 A118G×COMT rs4680(Recessive) .093 .108 16.1 .044 .046 4.5 .037 .021 
OPRM1 A118G×COMT rs4633(Recessive) .097 .102 5.2 .046 .049 6.5 .037 .038 
OPRM1 A118G×COMT rs4818(Dominant) -.044 -.058 31.8 .041 .048 17.1 .284 .223 
OPRM1 A118G×COMT rs6269(Recessive) -.075 -.070 6.7 .043 .047 9.3 .082 .136 
OPRM1 A118G×COMT LPS Haplotype -.047 -.059 25.5 .039 .045 15.4 .230 .194 
OPRM1 A118G×COMT APS Haplotype . 009 -.015 266.7 .039 .046 17.9 .818 .750 
OPRM1 A118G×COMT HPS Haplotype .001 -.073 7400 .059 .059 20.4 .982 .222 
OPRM1 A118G×COMT  Diplotypes .071 .047 33.8 .039 .044 12.8 .070 .285 
T*: Total sample, C**: Caucasian sample, %***: Percentage change. LPS= Low pain Sensitivity; APS= Average pain 
Sensitivity; HPS= High pain Sensitivity 
4.1.5 OPRM1 × COMT effect on postoperative pain 
The results of the regression analysis for predicting postoperative pain at 45 minutes in PACU by 
OPRM1 × COMT are summarized in Table 11. In addition to the main effects of both OPRM1 
and COMT, the interaction analysis controlled for gender, race, age, smoking, fracture type, 
preoperative pain, OR opioid consumption and opioid consumption during the first 45 minutes in 
PACU. Figure 9 shows the interaction effect of OPRM1 × COMT on postoperative pain where 
the pain variable was reflected and transformed using square root to meet the assumption of 
normality of model errors. Interaction graph represents the typical subjects in our sample; 
Caucasian, male, with ankle fracture, a mean age of 38.9, a mean OR opioid consumption of 
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0.246 mg/kg/hr, and a mean opioid consumption during the first 45 minutes in PACU of.08 
mg/kg.   
 
Table 11. Regression analysis summary for predicting postoperative pain by OPRM1 × COMT (Total sample) 
Interaction Variable n b 95%CI β p-value sr2 
 
OPRM1 A118G×COMT rs4680 
(Recessive) 
 
 
121 
 
0.444 
 
(-0.436,1.324) 
 
0.110 
 
.319 
 
.007 
OPRM1 A118G×COMT rs4633 
(Recessive) 
 
118 0.359 (-0.559,1.276) 0.083 .440 .004 
OPRM1 A118G×COMT rs4818 
(Dominant) 
 
117 -0.755 (-1.543,0.033) -0.276 .060 .024 
OPRM1 A118G×COMT rs6269 
(Recessive) 
 
116 -0.500 (-1.297,0.296) -0.199 .216 .010 
OPRM1 A118G×COMT LPS 
Haplotype 
 
121 -0.926 (-1.686, -0.166) -0.324 .017 .037 
OPRM1 A118G×COMT APS 
Haplotype 
 
121 0.288 (-0.510,1.085) 0.106 .476 .003 
OPRM1 A118G×COMT HPS 
Haplotype 
 
121 0.596 (-0.372,1.563) 0.137 .225 .010 
OPRM1 A118G×COMT  
Diplotypes 
 
121 0.637 (-0.132,1.407) 0.203 .103 .017 
Interaction analysis controlled for the main effects of both OPRM1 and COMT gender, race, age, smoking, fracture 
type, preoperative pain, OR opioid consumption and opioid consumption during the first 45 minutes in PACU. 
LPS= Low pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain Sensitivity 
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Figure 9. The interaction effect of OPRM1 × COMT (SNPs, haplotypes, and diplotypes) on 
postoperative pain at 45 minutes in PACU using total sample 
Graphs display the OPRM1 × COMT interaction effects for the typical subject in our sample; Caucasian, male, with 
ankle fracture, a mean age of 38.9, a mean OR opioid consumption of .246mg/kg/hr and a mean opioid consumption 
during the first 45 minutes in PACU of.08 mg/kg. Note: Pain variable was reflected and transformed using square root to 
meet the assumption of normality. , LPS= Low Pain Sensitivity; APS= Average Pain Sensitivity; HPS= High Pain 
Sensitivity. 
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A significant interaction was found between COMT LPS haplotype and OPRM1 A118G 
assuming a dominant genetic model (A118G/G118G vs. A118A), b = -0.93, p < .05. The effect 
of OPRM1 on postoperative pain varies across levels of COMT LPS haplotype. Considering 
having at least of one copy of LPS haplotype, there was a significant increase in pain score as we 
move from the wild type of OPRM1 (AA) to variants (AG/GG). Patients having at least one copy 
of COMT LPS haplotype and minor allele variants (AG/GG) of OPRM1A118G experienced 
more pain compared with patients having at least one copy of COMT LPS haplotype and AA of 
OPRM1A118G. However, not having the LPS haplotype was associated with the opposite 
direction, that is, there was a significant decrease in pain score as we move from the wild type of 
OPRM1 (AA) to variants (AG/GG). OPRM1A118G × COMT LPS haplotype accounted uniquely 
for 3.7% of the total postoperative pain variance. No significant interaction was found between 
OPRM1 and other COMT haplotypes and diplotypes. However, COMT diplotypes were 
significantly associated with postoperative pain in PACU, b = -0.321, p < .05, sr2 = .03. Patients 
having the high pain sensitivity diplotype experienced significantly more postoperative pain 
compared to patients having the low pain sensitivity diplotype, b=-0.321, 95%CI = [-0.636, -
0.005].  
No significant interaction was found between OPRM1 and COMT SNPs. However, the 
interaction of COMT rs4818 and OPRM1 assuming dominant genetic models was leaning 
towards significance (p = .06). The COMT SNP rs4633, assuming a recessive genetic model, was 
significantly associated with postoperative pain in PACU, b = -0.389, p<.05, sr2 = .03. Patients 
with two minor alleles T (TT) significantly experienced more postoperative pain at 45 minutes in 
PACU compared to patients having CT or CC, b=-0.389, 95%CI = [-0.759, -0.019]. Moreover, 
COMT rs4818 assuming a dominant genetic model was also significantly associated with 
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postoperative pain in PACU, b = 0.387, p < .05, sr2 = .04. Patients having one or two minor 
alleles G (GC and GG) significantly experienced more postoperative pain compared to patients 
having CC, b = 0.387, 95%CI = [0.051, 0.723]. The main effects of COMT rs4680 and rs6269 
assuming recessive genetic models were leaning towards significance with p-values of .063 and 
.055, respectively. 
None of OPRM1A118G × COMT SNPs, haplotypes and diplotypes was significantly 
associated with postoperative pain when the analysis was limited to Caucasian subjects (Table 
12). Figure 10 shows the interaction effect of OPRM1 × COMT on postoperative pain for the 
average/typical subject who was Caucasian and male, with ankle fracture, with a mean age of 
39.9 years, a mean OR opioid consumption of 0.233mg/kg/hr and a mean opioid consumption 
during the first 45 minutes in PACU of 0.08 mg/kg. The interaction effects for OPRM1A118G × 
LPS, OPRM1A118G × HPS, and OPRM1A118G × diplotypes were trending towards 
significance (p= .07, p= .058, p= .05, respectively). Table 13 represents the changes in regression 
statistics for postoperative pain data restricted to Caucasian subjects.  
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Table 12. Regression analysis summary for predicting postoperative pain in PACU by OPRM1× COMT 
(Caucasian only sample) 
Interaction Variable n b 95%CI Beta p-value sr2 
 
OPRM1 A118G×COMT rs4680 
(Recessive) 
 
 
95 
 
0.421 
 
(-0.501,1.342) 
 
0.121 
 
.366 
 
.007 
OPRM1 A118G×COMT rs4633 
(Recessive) 
 
92 0.419 (-0.526,1.364) 0.113 .380 .007 
OPRM1 A118G×COMT rs4818 
(Dominant) 
 
92 -0.486 (-1.390,0.420) -0.186 .289 .010 
OPRM1 A118G×COMT rs6269 
(Recessive) 
 
91 -0.640 (-1.470,0.188) -0.261 .128 .020 
OPRM1 A118G×COMT LPS 
Haplotype 
 
95 -0.794 (-1.660,0.067) -0.291 .070 .023 
OPRM1 A118G×COMT APS 
Haplotype 
 
95 0.080 (-0.811,0.971) 0.032 .858 <.001 
OPRM1 A118G×COMT HPS 
Haplotype 
 
95 1.110 (-0.04,2.261) 0.246 .058 .031 
OPRM1 A118G×COMT  
Diplotypes 
95 0.831 (-0.001,1.662) 0.281 .050 .033 
Interaction analysis controlled for the main effects of both OPRM1 and COMT gender, age, smoking, fracture type, 
preoperative pain, OR opioid consumption and opioid consumption during the first 45 minutes in PACU. LPS= Low 
pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain Sensitivity. 
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Figure 10. The interaction effect of OPRM1 × COMT (SNPs, haplotypes, and diplotypes) on pain at 
45 minutes in PACU for Caucasian subjects
Graphs display the OPRM1 × CPOMT interaction effects for the typical Caucasian subject who is male, with ankle 
fracture, a mean age of 39.9, a mean OR opioid consumption of .233 mg/kg/hr and a mean opioid consumption during 
the first 45 minutes in PACU of.08 mg/kg. Note: Pain variable was reflected and transformed using square root to 
meet the assumption of normality. , LPS= Low Pain Sensitivity; APS= Average Pain Sensitivity; HPS= High Pain 
Sensitivity. 
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Table 13. Changes and percentage changes in regression statistics of postoperative pain when the sample is 
restricted to Caucasians 
Interaction Variable bT* bC** %*** SET SEC % pT pC 
 
OPRM1 A118G×COMT rs4680(Recessive) 
 
 
.444 
 
.421 
 
5.2 
 
.444 
 
.463 
 
4.3 
 
.319 
 
.366 
OPRM1 A118G×COMT rs4633(Recessive) 
 
.359 .419 16.7 .463 .475 2.6 .440 .380 
OPRM1 A118G×COMT rs4818(Dominant) 
 
-.755 -.486 35.6 .398 .455 14.3 .060 .289 
OPRM1 A118G×COMT rs6269(Recessive) 
 
-.500 -.640 28.0 .401 .416 3.7 .216 .128 
OPRM1 A118G×COMT LPS Haplotype 
 
-.926 -.794 14.3 .383 .433 13.1 .017 .070 
OPRM1 A118G×COMT APS Haplotype 
 
.288 .080 72.2 .402 .448 11.4 .476 .858 
OPRM1 A118G×COMT HPS Haplotype 
 
.596 1.11 86.4 .488 .578 18.4 .225 .058 
OPRM1 A118G×COMT  Diplotypes 
 
.637 .831 30.5 .388 .418 7.7 .103 .050 
T*: Total sample, W**: Caucasian sample, %***: Percentage change. LPS= Low pain Sensitivity; APS= Average pain 
Sensitivity; HPS= High pain Sensitivity. 
4.2 DISCUSSION 
The purpose of this study was to explore OPRM1 and COMT gene-gene interaction effects on 
postoperative pain score and opioid consumption. Our findings showed that the interaction 
between OPRM1 and COMT partially explained the inter-individual variability in postoperative 
pain and response to opioids. To our knowledge, this is the first study to investigate the 
interaction of four COMT SNPs (rs6269, rs4633, rs4818 and rs4680) as well as COMT 
haplotypes and diplotypes with OPRM1 A118G SNPs to explain the variability in the pain 
phenotype. We found that combining the minor allele variants of both OPRM1 A118G and 
COMT Val158Met there was a poor response to opioid analgesia. Patients with the Met158Met 
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of COMT Val158Met and (AG/GG) of OPRM1 A118G combination consumed more opioid 
compared to patients with other combinations. Yao and colleagues found that cancer patients 
with this combination experienced higher preoperative pain sensitivity compared to other 
genotype combinations (Yao et al., 2015), in which, they had a lower pain threshold and pain 
tolerance threshold. Consistent with previous work of Reyes-Gibby et al, we found that carriers 
of the OPRM1 AA and COMT Met/Met genotype required the lowest opioid dose compared to 
other combinations (Reyes-Gibby et al., 2007). However, Landau et al. found that women with 
OPRM1 AA and COMT Met/Met genotype were associated with lower decrease in NVPS at 15 
minutes after single fentanyl dose during labor and delivery (Landau et al., 2013).  
This study is the first to include the interaction between OPRM1 A118G and silent SNPs 
of COMT (rs4633, rs4818 and rs6269). We found that patients having TT of COMT rs4633 and 
(AG/GG) of OPRM1 A118G consumed the largest amount of opioids compared to other 
combinations. Recent genetic studies focused on investigating haplotype reconstruction 
suggesting that combinations/ interactions of SNPs within haplotypes resulted in synergistic 
effects on the resultant protein and it might result in functional consequences that are different 
from the independent effects of those SNPs (Diatchenko et al., 2005; Duan et al., 2003). Thus, 
we expanded our analysis by including COMT haplotypes and diplotypes. We found that the 
Low Pain Sensitivity (LPS) haplotype has a “protective” effect on pain when combined with the 
wild type of OPRM1. Patients with the combination of OPRM1 A118A and LPS haplotype 
reported the lowest pain score compared to all other combinations. Moreover, patients with the 
high pain sensitivity diplotype reported higher pain compared to those with the low pain 
sensitivity diplotype. 
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It has been found that the synonymous” silent” SNPs of COMT gene could affect mRNA 
stability and consequently COMT protein expression and enzymatic activity (Nackley et al., 
2006). Previous pain genetic studies showed that silent SNPs of the COMT gene (rs4633, rs4818 
and rs6269) influence pain sensitivity and opioid efficacy (Lee et al., 2011; Rut et al., 2014). 
Consistent with that, we found that the two synonymous SNPs of COMT, rs4633 and rs4818, 
were significantly associated with postoperative pain in the PACU. The TT of rs4633 and 
AG/GG of rs4818 interaction was associated with higher pain sensitivity compared to other 
combinations for these SNPs. 
Some of our findings on postoperative pain were changed after restricting the analyses to 
Caucasians. For example, the significant interaction of OPRM1 and LPS haplotype using the 
total sample was not significant in Caucasians. Both OPRM1×ACCG and OPRM1×diplotypes 
showed a trend toward significance in Caucasians that was not observed when using the total 
sample. The changes in our findings might be partly due to the variation in the allele and 
haplotype frequencies among the different racial populations (Beuten, Payne, Ma, & Li, 2006; 
DeMille et al., 2002; Gabriel et al., 2002; Hastie et al., 2012; Palmatier, Kang, & Kidd, 1999). In 
conclusion, our findings suggest the OPRM1×COMT gene-gene interaction may contribute to the 
variability of postoperative pain and response to opioids. Future studies with larger sample sizes 
and more diversity are needed to confirm these effects. 
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5.0  MANUSCRIPT #1: GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS 
PREDICT PAIN PHENOTYPES: A REVIEW OF THE LITERATURE 
5.1 ABSTRACT 
 
Purpose: The aim of this paper was to review the existing literature in the area of gene-gene and 
gene-environment interactions related to pain phenotypes. 
Organizing Construct: This review examined previous literature in the area of gene-gene and 
gene-environment interactions related to pain. The review focuses on the gene-gene interaction 
of OPRM1 and COMT and its effect on predicting pain and opioid efficacy, and finally it reviews 
the effects of other gene-gene and gene-environment interactions related to phenotypes of pain. 
Findings: Gene-gene and gene-environment interactions are significant factors affecting the 
various disease susceptibility and predicting complex pharmacologic responses including pain 
sensitivity and opioid efficacy. A single gene alone is not likely to be responsible for all variation 
in pain sensitivity or opioid efficacy.  But more of the variation in responses to pain may be able 
to be explained by evaluating the interaction of various genes and environmental factors 
associated with pain pathways. 
Conclusion: Gene-gene and gene-environment interactions may be a way to explain the complex 
mechanisms associated with the various phenotypes including pain and opioid efficacy.  
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Clinical Relevance: Exploring the gene-gene and gene-environment interactions may lead to 
more precise risk prediction of pain phenotype. Subsequently, it could improve current strategies 
to personalized pain management. Personalized pain management can be an effective strategy to 
maximize the usefulness of pain treatment and minimize complications and adverse effects 
associated with opioids.  
Key Words: gene interaction, epistasis, gene-environment interactions, pain, analgesics, opioid. 
5.2 INTRODUCTION 
The complex relationship between genotype and phenotype is partially explained by the 
interactions among genes. At the cellular level, gene-gene interaction is the interaction between 
alleles at different loci to express a single trait. However, from a statistical standpoint, gene- 
gene interaction represents the deviation from a statistical additive mode that describes how two 
or more variables predict a phenotype (Fisher, 1918). The integration of the statistical interaction 
models into the biological mechanisms is still challenging.  
Gene-gene interaction is a significant factor that affects various human traits, disorders, 
diseases, and drug responsiveness (Dean, 2003; Dean et al., 1996; Rivolta, Sharon, DeAngelis, & 
Dryja, 2002; Shin et al., 2000; Smith et al., 1997). In this review, we provided a brief 
introduction of gene-gene interaction role in predicting human complex diseases and 
pharmacologic treatment response. Then we focus on the effect of OPRM1 and COMT gene-
gene interaction on the phenotypes of pain and opioid efficacy. We discussed evidence to 
support the importance of the interaction of these genes in predicting pain and opioid efficacy. 
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Finally, we highlighted evidence for other gene-gene and gene-environment interactions related 
to pain phenotype. 
5.3 GENE INTERACTIONS PREDICT VARIOUS HUMAN COMPLEX DISEASES 
AND PHARMACOLOGIC TREATMENT RESPONSE 
Complex human traits involve various biological and biochemical pathways, each is influenced 
by multiple genes. Thus, examining the gene interactions instead of a single gene might explicate 
the disease underlying biological mechanisms and pathways, which in turn, improve the 
understanding of complex disease etiology. Various genetics studies have described the effect of 
gene-gene interaction on human complex diseases such as asthma, cancers, diabetes, 
inflammatory bowel disease, psychiatric disorders, systemic lupus erythematosus and others 
(Chan et al., 2008; Chen et al., 2009; Hughes et al., 2012; Lin, Hong, et al., 2009; Manso et al., 
2012; Polgar et al., 2012; Ryu et al., 2011; Turnbull et al., 2012; Xiao et al., 2011).  
Gene-gene interaction has also played an important role in predicting complex 
pharmacologic treatment responses and mechanisms (Lane, Tsai, & Lin, 2012). It has helped in 
predicting high risk individual for drug under-treatment or over-treatment. Evidence has shown 
that gene-gene interaction has been significantly associated with treatment responsiveness of 
various drugs including; IFNa and ribavirin for treating Chronic Hepatitis C (CHC) (Lin, Hwang, 
& Chen, 2007), Sibutramine for weight loss (Hsiao, Wu, Hwang, Huang, & Lin, 2010) , 
albuterol for asthma treatment (Choudhry et al., 2010; Corvol et al., 2009), and methotrexate for 
rheumatoid arthritis therapy (Sharma et al., 2008)..Etc.  
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5.4 THE INTERACTIONS BETWEEN LINKED GENES IS A VALUED STRATEGY 
TO BE CONSIDERED TO BETTER EXPLAIN HUMAN TRAITS 
Genetic studies often consider the effect of individual genes or haplotypes on phenotypes 
ignoring the possible effect of their interactions. However, evidence shows that gene-gene 
interaction can significantly predict various phenotypes in the absence of an independent main 
effect of a single gene (Manso et al., 2012; Moore & Williams, 2002; Nelson, Kardia, Ferrell, & 
Sing, 2001). Nelson and colleagues identified gene-gene interaction between multiple loci from 
six cardiovascular disease susceptibility genes, in which gene-gene interactions explained the 
inter-individual variability in plasma triglycerides whereas evaluating only SNPs failed to predict 
such variability (Nelson et al., 2001). Manso and colleagues investigated  the contribution of 
three growth factor genes; BDNF, FGF2, and VEGFA  on recovery after stroke, while none of 
those genes was independently associated with stroke outcome, two significant gene–gene 
interactions were identified (Manso et al., 2012). A pharmacogenomics study of major 
depressive disorder evaluated four serotonin-related genes (GNB3, HTR1A, HTR2A, and 
SLC6A4) on antidepressant treatment outcomes. Only one SNP of four (GNB3 rs5443) was 
found to be associated with antidepressant treatment outcome whereas the interaction analyses 
revealed that there were 2 significant locus gene-gene interactions between GNB3 and HTR2A, 
as well as a significant 3rd  locus gene-gene interaction among GNB3, HTR2A, and SLC6A4. 
Those finding suggesting that serotonin-related genes contribute to the short-term antidepressant 
treatment outcome in an interactive manner (Lin, Chen, et al., 2009). Taken together, complex 
human traits might not explained only by the independent main effect of genes. Exploring the 
gene-gene interaction may lead to more precise risk prediction of human traits. 
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5.5 GENE-GENE INTERACTIONS IN PAIN GENETICS STUDIES 
According to the Pain Genes Database, 300 candidate genes have been identified as being 
associated with pain (Lacroix-Fralish, Ledoux, & Mogil, 2007). Genetic variants in those genes 
are known to affect pain sensitivity, analgesic efficacy, and the incidence of analgesia adverse 
effects such as, nausea, vomiting and sedation (Stamer & Stuber, 2007). Pain is a complex 
phenomenon that might be better explained with gene-gene interactions rather than with a single 
SNP. Therefore, gene-gene interaction may influence the human experience of pain and explain 
the inter-individual differences. However, gene interaction studies of pain and opioid efficacy are 
limited. Few studies investigated the gene–gene interaction of pain related gene; OPRM1, 
COMT, CYP3A4 and ABCB1/MDR1 on pain sensitivity and opioid efficacy (Campa, Gioia, 
Tomei, Poli, & Barale, 2008; De Gregori et al., 2013; Kolesnikov, Gabovits, Levin, Voiko, & 
Veske, 2011; Landau, Liu, Blouin, & Carvalho, 2013; Liao et al., 2013; Matic et al., 2014; 
Reyes-Gibby et al., 2007; Yao et al., 2015). OPRM1 and COMT are by far the most extensively 
studied pain genes. Thus, the focus of this paper is the interaction between those genes. The 
following sections highlight some of evidence to support the importance of OPRM1 and COMT 
and their interaction effects on predicting pain sensitivity and opioid efficacy. 
5.5.1 OPRM1 and COMT are considered the genes most associated with pain sensitivity 
and opioid efficacy. 
The main effect of each of OPRM1 and COMT genes on pain sensitivity and opioid efficacy are 
well established in the pain literature. OPRM1 is the gene that encodes for the mu receptor, the 
primary site of action for endogenous and exogenous opioids (Bond et al., 1998; Zadina, 
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Hackler, Ge, & Kastin, 1997). The A118G polymorphism is the most common single nucleotide 
polymorphism (SNP) of OPRM1. In this mutation asparagine is changed to aspartic acid at 
position 40 of the resultant gene product. This substitution results in less mRNA expression in 
brain tissues of G allele carriers (Y. Zhang et al., 2005). Moreover, the G118 has a secondary 
structure alteration that affects its expression and translation into functional protein; mRNA of 
G118 showed a well predicted helix that does not exist in the other variant structures. 
Furthermore, the G118 mRNA structures does not contain a loop motif that all OPRM1 variants 
commonly contain (Zhang, Wang, Johnson, Papp, & Sadee, 2005). Given this finding, carriers of 
the G allele were found to experience more pain and need higher opioid dose to achieve adequate 
pain control compared with those with the wild-type A118 (Chou, Yang, et al., 2006; Sia et al., 
2008; Tan et al., 2009). 
Catechol-O-methyltransferase (COMT) is one of several enzymes responsible for 
metabolizing and degrading catecholamines. Genetic variants in the gene coding for COMT have 
been found to influence opioid pathways. COMT Val158Met is the most common SNP of COMT 
in which the substitution of valine to methionine at codon 158 leads to a 3- to 4-fold decrease in 
COMT activity (Lotta et al., 1995). The Met/Met genotype is associated with the lowest activity 
of COMT enzyme, followed by Met/Val and Val/Val genotypes with the intermediate and 
highest activity respectively. It has been shown that the decrease in enzyme activity reduces the 
content of enkephalins in certain brain regions and consequently increase pain sensitivity 
(Zubieta et al., 2003). In view of this finding, clinical studies have shown the patients with 
homozygous Met experience more pain compared with Val/Val and Val/Met (Kolesnikov et al., 
2011; Rakvag et al., 2005). 
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5.5.2 Both genes interact on  the neurotransmission pathways of pain  
Cumulative evidence shows that COMT Val158Met affects mu receptor (OPRM1) availability, 
expression and density in brain tissue by affecting enkephalin levels, which inversely regulate 
mu receptor expression. Accordingly, the number of mu-opioid receptor binding sites is affected 
by COMT Val158 Met polymorphism such that COMT Met158 allele carriers are significantly 
associated with the highest mu receptor expression and lowest enkephalin peptide levels 
compared with other COMT Val158 Met genotypes. (Berthele et al., 2005; Kowarik et al., 2012; 
Zubieta et al., 2003).  
COMT Val158Met has been shown to affect the number of binding sites of mu opioid 
receptors using Positron Emission Tomography (PET) and the radiotracer [11C] carfentanil, a 
mu receptor ligand. Met158 allele of COMT Val158Met demonstrated highest binding potential 
of [11C] carfentanil compared with the Val158 homozygotes. The high levels of dopamine are 
caused by Met at position 158 in the COMT protein led to a reduction in enkephalin levels and 
consequently, mu receptor expression is upregulated (Zubieta et al., 2003). Ligand binding 
autoradiography ([3H] DAMGO receptor) in post-mortem tissue has also been used to confirm 
the effect of COMT Val158Met polymorphism on mu receptor binding site expression in the 
human brain. Met158 allele of COMT was associated with a higher expression of mu binding 
sites in various brain regions including the caudate nucleus, the nucleus accumbens and the 
mediodorsal nucleus of the thalamus (Berthele et al., 2005). Recently, Kowarik and colleagues 
examined the effect of the COMT Val158Met polymorphism on mu receptor using 
semiquantitative immunostaining on post-mortem human brain tissues. The Met158 
homozygotes expressed significantly more mu receptor protein than Val158 homozygotes in 
human basal ganglia and thalamic tissues. Moreover, the lowest levels of enkephalin peptide 
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were found in Met158 homozygote tissues, whereas Val158 homozygotes showed the highest 
peptide levels. Accordingly, the COMT Val158Met polymorphism might influence the mu 
receptor expression through use-dependent down/up-regulation secondary to altered enkephalin 
levels (Kowarik et al, 2012). Since Interactions between the dopaminergic and opioidergic 
system are recognized as explained above, gene-gene interaction of COMT and OPRM1 may 
influence the human experience of pain and explain the inter-individual differences. 
5.5.3  Findings of previous studies investigating the main effects of OPRM1 or COMT 
failed to be replicated 
Several studies have investigated the association between the single gene effects of OPRM1 or 
COMT and the variability in acute or chronic pain and opioid efficacy. However, overall 
contradictory results have been obtained (Campa et al., 2008; Chou, Wang, et al., 2006; Chou, 
Yang, et al., 2006; Coulbault et al., 2006; Hayashida et al., 2008; R. A. Henker et al., 2012; 
Janicki et al., 2006; Kim, Clark, & Dionne, 2009; Kim et al., 2004; Klepstad et al., 2004; 
Kolesnikov et al., 2011; Rakvag et al., 2005; Rakvag et al., 2008; Reyes-Gibby et al., 2007; Ross 
et al., 2008; Tan et al., 2009). For instance, examining the genetic effect of A118G SNP of 
OPRM1 on pain and response to opioids has shown that patients with the OPRM1 A118G 
polymorphism who were homozygous for the variant G allele were reported to need more 
morphine to achieve adequate post-operative pain control compared with the those homozygous 
for the wild-type A118 allele (Chou, Wang, et al., 2006; Chou, Yang, et al., 2006; Hayashida et 
al., 2008; Sia et al., 2008; Tan et al., 2009). However, other studies did not find a statistically 
significant association between presence of the A118G polymorphism and the dose of opioid 
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required for pain relief (Coulbault et al., 2006; Richard A. Henker; Janicki et al., 2006; 
Kolesnikov et al., 2011).  
Conflicting results were also found among studies investigating the impact of the COMT 
gene on pain sensitivity and opioid efficacy. Some genetic studies found that patients with the 
Val/Val genotype consumed a significantly higher opioid dose to manage their pain, compared to 
those with the Met/Met and Val/Met genotypes (Henker et al., 2013; Rakvag et al., 2005). 
However, other studies did not find the same association between COMT Val158Met presence 
and opioid dose requirement (Kolesnikov et al., 2011; Ross et al., 2008).  
The inability to replicate prior genetics studies investigating the main effect of OPRM1 or 
COMT has several explanations.  First, previous studies included heterogeneous samples using 
different racial/ethnic groups, different diagnoses and different surgical operations. Second, the 
relatively small sample sizes in prior studies might not have the sufficient statistical power to 
adequately detect the differences among polymorphisms. Third, the low frequency of the rare 
G118 allele in some of prior studies investigating OPRM1 A118G might also reduce the 
statistical power. Finally, prior studies considered the effect of individual genes or haplotypes 
ignoring the possible effects of their interactions. The failure of single locus studies’ findings to 
be replicated may indicate that the impact of gene-gene interaction is more crucial than the single 
SNPs effect. Since gene effects alone may not be responsible for all variation in pain and opioids 
efficacy. The interaction of various pain genes may ensure better explanation for wide variability 
in pain sensitivity and opioid efficacy (Kolesnikov et al., 2011; Reyes-Gibby et al., 2007).   
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5.5.4 Gene-gene interaction of OPRM1 and COMT is one of the most extensively studied 
gene interactions in relation to the pain phenotype 
The interaction effect of COMT Val158Met and OPRM1 A118G has been found to explain 
variability in acute postoperative or chronic cancer pain sensitivity and opioid efficacy (De 
Gregori et al., 2013; Kolesnikov et al., 2011; Landau et al., 2013; Matic et al., 2014; Reyes-
Gibby et al., 2007; Yao et al., 2015). Regarding chronic cancer pain; Reyes-Gibby et al found 
that cancer patients who carry OPRM1 A118A and COMT Met158Met genotype required the 
lowest morphine dose to achieve adequate pain control. On the other hand, the patients who did 
not carry Met158Met or A118A genotype at all requested the highest morphine dose. Moreover, 
the morphine requirement in the joint effect of both OPRM1 and COMT genotype was lower 
than in the single effect for these SNPs alone (Reyes-Gibby et al., 2007). Yao and colleagues 
found that cancer patients undergoing elective surgery with the combination of G118G of 
OPRM1 and Met158Met of COMT had a more significant decrease in pain threshold and pain 
tolerance (Yao et al., 2015). 
Four studies were found to investigate the gene-gene interaction between OPRM1 A118G 
and COMT Val158Met in relation to acute postoperative pain. Kolesnikov et al investigated the 
combined effect of OPRM1 A118G and COMT Val 158Met on postoperative pain and opioid 
efficacy after abdominal surgery (Kolesnikov et al., 2011). Patients with A118G and Val158Met 
combination needed significantly fewer morphine doses, approximately 18% less morphine, 
during the first 48 hours postoperatively compared with  OPRM1 A118A (Kolesnikov et al., 
2011). De Gregori et al examined the interaction effect of these genes on opioid consumption 
after major abdominal and urological surgery. However, no significant differences in opioid 
consumption during the first 24 postoperative hours was found (De Gregori et al., 2013). 
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Recently, Landau et al investigated the effect of COMT and OPRM1 on analgesic response to 
intravenous fentanyl during labor and delivery. It has been found that women with the 
combination of OPRM1 A118A and COMT Met158Met have lower decrease in numerical verbal 
pain score (NVPS) at 15 minutes after receiving an IV fentanyl dose compared to other genotype 
combinations. However, there was no significant differences in term of analgesic response to IV 
fentanyl between women with the OPRM1 A118A and COMT Met158Met combination 
compared to women with other allelic combination (Landau et al., 2013). Lastly, Matic et al. 
investigated the effect of COMT and OPRM1 on rescue morphine requirement (yes/no) and total 
morphine consumption in newborns under mechanical ventilation (Matic et al., 2014). The 
combination of OPRM1 118G allele and COMT Val158Val was significantly associated with the 
need for morphine rescue. However, this combination was not associated with total morphine 
consumption. 
The findings of previous genetic studies investigating the interaction effects between 
OPRM1 and COMT have not been replicated. Moreover, findings from those studies are 
troublesome to compare because of the major differences among studies. Previous studies 
investigating the interaction between OPRM1 and COMT used different types and causes of 
pain; (acute postoperative versus chronic cancer pain), (preoperative versus postoperative pain), 
and (experimentally induced pain versus clinical pain). Furthermore, the definition and 
assessment of the final pain outcome varies among those studies; (pain sensitivity versus pain 
threshold and pain tolerance) and (pain at specific time point versus the decrease in pain from 
baseline). Finally, various opioid regimens were used to examine pain response including; long-
term opioid therapy, short-term postoperative therapy, single opioid dose and rescue morphine 
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requirement. These differences make it difficult to compare findings from those studies and draw 
general conclusions about the interaction effect of OPRM1 and COMT genes on pain. 
5.5.5 Other evidence of gene-gene interactions in the area of pain genetics 
Genetic pain studies have investigated the interactions of other genes involved in pain sensitivity 
and opioid efficacy. Two studies were conducted to investigate the interaction effect of OPRM1 
A118G and ABCB1/MDR1on pain-related phenotypes. The ABCB1/MDR1 gene codes for a P-
glycoprotein efflux transporter, which transports various substrates including drugs across the 
cell membrane and blood–brain barrier (Mizutani et al., 2008; Wandel, Kim, Wood, & Wood, 
2002). The first study investigated the interaction effect of OPRM1 A118G and ABCB1 C3435T 
in term of pain relief after morphine administration for cancer patients (Campa et al., 2008). No 
significant interaction between of OPRM1 A118G and ABCB1/MDR1 C3435T was found. 
However, a simple additive effect of single allele combination has been shown. For instance, 
cancer patients with the combined ABCB1 TT and OPRM1 AA showed significantly greater pain 
relief after morphine administration than patients with either ABCB1 TT or OPRM1 AA. The 
second study investigated the interaction of OPRM1 A118G and ABCB1 haplotypes on 
methadone dose and trough plasma (R)-methadone concentrations (Ctrough) for opioid-dependent 
subjects (Barratt et al., 2012). Among OPRM1 A118A subjects, there was a significant 
difference in methadone dose and Ctrough between ABCB1 haplotype groups, with the AGCTT 
variant haplotype (61A; 1199G; 1236C; 2677T; 3435T) associated with a significantly lower 
dose and Ctrough than the wild-type ABCB1 subjects. Among subjects with the ABCB1 
AGCGC/AGTTT haplotype combination, the OPRM1 A118G genotype was associated with 
significantly higher Ctrough than the A118A.  
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Liao and colleagues investigated the interaction between OPRM1 and CYP3A4 on 
postoperative fentanyl analgesia in Chinese Han patients undergoing radical gastrectomy (Liao et 
al., 2013). CYP3A4 encodes the cytochrome P450 enzymes which catalyze many reactions 
involved in drug metabolism (Labroo, Paine, Thummel, & Kharasch, 1997). A significant 
interaction between OPRM1 A118G and CYP3A4*18B polymorphisms was found, in which 
patient with combined AG of OPRM1 A118G and *1*1 of CYP3A4 received larger fentanyl 
doses compared with those with AA and *1*18B or those with AG and *1*18B. However, the 
interaction of OPRM1 and CYP3A4 on postoperative nausea, vomiting and dizziness was not 
significant.   
5.6 GENE-ENVIRONMENT INTERACTIONS IN PAIN GENETICS STUDIES 
Several studies have investigated the interaction between pain genes and environmental factors 
to explain the variability in pain sensitivity and opioid efficacy. Hastie and colleagues 
investigated the ethnic differences in OPRM1 allelic association with experimental pain 
responses (Hastie et al., 2012). Three different ethnic groups including African Americans, non-
White Hispanics and non-Hispanic whites were included. Across the three ethnic groups, 
OPRM1 genotype did not significantly affect pain sensitivity. However, when each ethnic group 
was analyzed separately there was a significant effect of OPRM1 for most pain modalities only 
in the non-Hispanic White group. Specifically, the G allele was associated with decreased pain 
sensitivity in this group. The author suggested that the ethnicity-dependent association of 
OPRM1 with pain sensitivity could be due to linkage with other functional polymorphisms or 
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gene–gene interactions with other variants with different frequency among ethnic groups (Hastie 
et al., 2012). 
Gene-sex interactions have also been shown to explain the inter-individual variability in 
pain. Rhodin and colleagues investigated the sex- ABCB1 C3435T interaction on plasma β-
endorphin level in chronic low back pain patients (Rhodin et al., 2013). It has been found that 
men with the minor TT allele of ABCB1 had higher β-endorphin levels than men with the major 
CC allele but the reverse was true for women (Rhodin et al., 2013). Two recent studies have 
investigated sex -OPRM1 A118G interaction on pain sensitivity. Olsen et al found that OPRM1 
G allele increases the pain intensity in women, but has a protective effect in men the first year 
after disc herniation. Moreover, the G allele women had 2.3 times as much pain as the G allele 
men (Olsen et al., 2012). Hasvik et al found that all patients, with lumbar radicular pain and disc 
herniation, except female carriers of the OPRM1 G-allele reported a decrease in pain from 
baseline to 1 year (Hasvik et al., 2014). Moreover, female carriers of the G-allele reported a 
significantly higher subjective health complaint score than male carriers of the G-allele when 
controlling for pain and pain duration (Hasvik et al., 2014). The differences in the type and level 
of glycosylation site of the mu receptor between men and women is a possible explanation for 
the sex-specific differences of OPRM1 (Ding et al., 2011). Belfer and colleagues investigated the 
sex differences in the effect of COMT variants on capsaicin-induced pain in mice and humans 
(Belfer et al., 2013). The COMT High Pain Sensitivity haplotype (ATCA; HPS) was significantly 
associated with higher pain in females compared to males in both species. Sex differences in 
COMT HPS haplotype effect on pain could possibly be explained by that fact that females have 
lower COMT levels compared to men. Furthermore, males have additional receptor pathways 
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stimulated by catecholamines that are not as functional in females. Thus, compared with males, 
females tend to be more sensitive to pain (Belfer et al., 2013). 
Interactions between genetic and psychological factors were also found to be predictors 
of pain. George and colleagues found significant interactions between the COMT diplotype and 
pain catastrophizing on postoperative pain for patients receiving operative treatment of shoulder 
pain (George, Dover, et al., 2008). Patients with high pain catastrophizing and low COMT 
activity (APS/HPS group) were found to be more likely to have post-operative pain ratings of 
4.0/10 or higher (George, Wallace, et al., 2008). In another study the same author investigated 
the interactions between COMT diplotype and pain catastrophizing using experimental pain 
model. Delayed Onset Muscle Soreness (DOMS) was induced at the shoulder (George, Dover, et 
al., 2008). Findings from this experimental pain model converge with those from their previous 
clinical pain model; as participants with high pain catastrophizing and low COMT enzyme 
activity (APS/HPS group) were more likely to have elevated pain intensity ratings (40/100 or 
higher). 
5.7 CONCLUSION 
Pain is a subjective multidimensional human experience. Thus, interaction of various pain genes 
and environmental factors may provide better explanation for the wide variety in pain sensitivity 
and opioid efficacy. Exploring the gene-gene and gene-environment interactions may help 
establish personalized pain management to achieve effective pain control and minimize risk 
of opioid adverse effects. 
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6.0  MANUSCRIPT #2: OPRM1 AND COMT GENE–GENE INTERACTION IS 
ASSOCIATED WITH POSTOPERATIVE PAIN AND OPIOID CONSUMPTION AFTER 
ORTHOPEDIC TRAUMA SURGERY 
6.1 ABSTRACT 
Background: OPRM1 (mu-opioid receptor) and COMT (Catechol-O-Methyltransferase) 
contribute to the neurotransmission pathway of pain. Evidence shows that COMT affects mu 
receptor availability, expression and density in brain tissue. Thus, investigating the interaction of 
COMT and OPRM1 on pain and pain management is warranted. The aim of this study was to 
explore the OPRM1 and COMT interaction on postoperative pain and opioid consumption.  
Method: This cross-sectional study used genotype and clinical data from 153 postoperative 
orthopedic trauma patients. Using multiple regression analyses, four single nucleotide 
polymorphisms of COMT ( rs6269, rs4633, rs4818 and rs4680), their haplotypes and diplotypes 
were considered for their interactions with A118G of OPRM1on postoperative pain and opioid 
consumption. All analyses were performed in the total sample and in Caucasian-only patients.  
Results: For postoperative opioid consumption, a significant interaction was found between 
OPRM1 A118G and COMT rs4680 (p=.037). Patients having Met158Met of COMT rs4680 and 
(AG/GG) of OPRM1 consumed the largest opioid compared to other combinations. A significant 
interaction was also found between OPRM1 and COMT rs4633 (p=.037). Patients having TT of 
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COMT rs4633 and (AG/GG) of OPRM1 consumed the largest amount of opioid compared to 
other combinations. The results for OPRM1×COMT rs4680 and OPRM1×COMT rs4633 on 
opioid consumption were maintained even after restricting the analyses to Caucasian subjects. 
For postoperative pain, a significant interaction was found between OPRM1 and the Low Pain 
Sensitivity (LPS; GCGG) haplotype of COMT (p=.017). For patients with no copies of the LPS 
haplotype, (AA) of OPRM1 A118G was significantly associated with higher pain scores 
compared to the variant (AG/GG). However, the opposite direction was observed for patients 
with at least one copy of LPS haplotype. When the sample was limited to Caucasian, only a trend 
was observed for the interaction of OPRM1 and LPS haplotype on postoperative pain (p=.070).  
Conclusions and Clinical Relevance: OPRM1×COMT interaction appears to be important to 
postoperative pain and response to opioids. Individualized pain management based on genetic 
variations might improve future strategies for pain management. 
6.2 INTRODUCTION 
Inadequate relief of postoperative pain may result in many harmful physiological, psychological 
and behavioral consequences that have a significant impact on morbidity and mortality as well as 
health care costs (Caudill-Slosberg et al., 2004; Feeney, 2004; Janssen et al., 2004; Joshi & 
Ogunnaike, 2005). The highly individualized effect of opioids on patients makes optimal pain 
management challenging. Genetic variations have been suggested as a possible explanation for 
variation in pain intensity and response to opioids. 
The single nucleotide polymorphism (SNP) effects of OPRM1 and COMT gene on the 
variability in pain and response to opioids are well established. The variant alleles of both 
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OPRM1 A118G (AG and GG) and COMT Val158Met (Met/Met) SNPs have been reported to be 
independently associated with higher postoperative pain compared to their wild types (Henker et 
al., 2013; Klepstad et al., 2004; Kolesnikov et al., 2011; Sia et al., 2013; S. Zhang, Li, & Tan, 
2013). The G variant of OPRM1 A118G was also associated with larger opioid consumption 
(Chou, Yang, et al., 2006; Klepstad et al., 2004; Sia et al., 2013; S. Zhang et al., 2013). However, 
evidence suggests that the relationships between these genes and pain are more complex and 
might involve interaction of multiple genes (Landau et al., 2013; Reyes-Gibby et al., 2007). 
COMT genetic variants have been found to affect mu receptor (OPRM1) availability, expression 
and density in brain tissue by affecting enkephalin levels, which inversely regulate mu receptor 
expression (Berthele et al., 2005; Kowarik et al., 2012; Zubieta et al., 2003). Therefore 
OPRM1×COMT interaction may significantly impact pain perception and response to opioids. 
The interaction effect of OPRM1 A118G and COMT Val158Met was first evaluated on 
opioid dose needed to control cancer pain. Carriers of OPRM1 AA and COMT Met/Met 
genotype require the lowest opioid dose to relieve pain (Reyes-Gibby et al., 2007). However, in 
another study, women with that combination had the least pain relief after intravenous fentanyl 
dose during labor and delivery (Landau et al., 2013). De Gregori et al did not find significant 
interactions between these genes on postoperative opioid consumption (De Gregori et al., 2013). 
Lastly, cancer patients undergoing elective surgery with OPRM1 GG and COMT Met/Met 
genotype have lowest preoperative pain threshold and tolerance (Yao et al., 2015). As shown a 
bove, the findings of OPRM1 and COMT interaction studies have not been replicated. The 
definition of pain outcomes and opioid regimens vary among those studies make it difficult to 
compare their findings and draw general conclusions. 
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Haplotype is a set of closely linked SNPs on the chromosome that are inherited as a unit. 
Diatchenko used the four COMT SNPs; rs6269, rs4633, rs4818, and rs4680 to define three major 
pain-sensitivity haplotypes; low pain sensitivity (LPS; GCGG), average pain sensitivity (APS; 
ATCA) and high pain sensitivity (HPS; ACCG) (Diatchenko et al., 2006). No published studies 
have investigated the interaction of COMT haplotypes or diplotypes (i.e., combination of 
haplotypes) with OPRM1 on pain and opioid consumption. 
The purpose of this study was to explore the gene-gene interaction of COMT and OPRM1 
on postoperative pain and opioid consumption in orthopedic trauma patients. This is the first 
study to investigate the interaction of four COMT SNPs (rs6269, rs4633, rs4818 and rs4680) as 
well as COMT haplotypes and diplotypes with OPRM1 A118G on postoperative pain and opioid 
consumption. 
6.3 MATERIALS AND METHODS 
6.3.1 Subjects 
This cross-sectional descriptive study used previously obtained phenotype, demographic, clinical 
and genotyping data from a parent study (Henker et al., 2013).  Incluion criteria for that study 
were: patients from 18 to 80 years of age, who received general, and had a single orthopedic 
surgery with planned surgical time of 1 to 4 hours in length. Patients were excluded if they had a 
second trauma site, history of mental illness, neurologic conditions, hepatic or renal disease. 
Subjects were prospectively enrolled in the parent study after written informed consent was 
obtained. Human subjects approval was obtained from the University of Pittsburgh 
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Institutional Review Board.  Demographic and clinical data were collected from the patients and 
their medical records. 
6.3.2 Postoperative pain and opioids 
Pain was assessed using the Numeric Rating Scale (NRS), an 11-point verbal pain response scale 
from 0 (“no pain”) to 10 (“pain as bad as I can imagine”). Pain scores were collected in the 
preoperative holding area and then at 45 minutes after arrival in the PACU. Opioids administered 
during PACU stay included fentanyl, hydromorphone, morphine, and meperidine. The amount of 
opioid administered was converted to morphine equivalents, where 100 mg fentanyl, 1.5 mg 
hydromorphone, or 75 mg of meperidine were equivalent to 10 mg of morphine (Berry & C., 
2006). 
6.3.3 Genotyping data 
Oragene DNA self-collection kit from DNA Genotek Incorporated (Ottawa, Ontario, Canada) 
was used to collect saliva samples from patients and DNA was extracted using the manufacture’s 
protocol. OPRM1 A118G (rs1799971) was genotyped using sequencing and coded into two 
levels; no minor allele G “wild” and 1 or 2 minor allele G “variant”. 
The four COMT SNPs including rs6269, rs4633, rs4818, and rs4680 were genotyped 
using 5' exonuclease Assay-on-Demand TaqMan assays. The Haploview software 
(http://www.broad.mit.edu/mpg/haploview) was used to visualize the pairwise linkage 
disequilibrium (LD) between the selected four COMT SNPs measured by Lewontin’s D' (Barrett, 
Fry, Maller, & Daly, 2005) (Figure 11). COMT haplotypes, constructed from the four COMT 
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SNPs, were designated as low pain sensitivity (LPS), average pain sensitivity (APS) and high 
pain sensitivity (HPS) (Diatchenko et al., 2006). COMT haplotypes were coded into two levels as 
‘having no copies’ and ‘having at least one copy’. Using combinations of these three major 
haplotypes, we created two diplotypes; low pain sensitivity (LPS/LPS or LPS/APS) and high 
pain sensitivity (APS/APS, HPS/HPS, LPS/HPS or APS/HPS). Details for sample collection and 
genotyping procedure were previously described by Henker et al. (Henker et al., 2013). 
6.3.4 Statistical analysis 
All statistical analyses were preceded by detailed descriptive and exploratory analyses of the 
data. Hardy–Weinberg equilibrium (HWE) was assessed for all genotyped SNPs using the exact 
test implemented in the software PLINK (Purcell et al., 2007). Hierarchical multiple regression 
analyses were performed with postoperative pain scores at 45 minutes in PACU and opioid 
consumption during PACU stay as dependent variables. Square root transformation of reflected 
values of postoperative pain score were used for regression analyses to remediate the violation of 
normality assumption for model residuals. Independent variables were: OPRM1 A118G (under 
dominant genetic model), the four COMT SNPs including rs6269, rs4633, rs4818 and rs4680 
(under additive, dominant, and recessive genetic models), the three COMT haplotypes (low, 
average, and high pain sensitivity), and COMT diplotypes (low and high pain sensitivity). The 
main and interaction effects of the independent variables were investigated after adjustment for 
covariates identified from the literature. Gender, race/ethnicity, age, smoking, fracture type and 
OR opioids consumption (mg/kg/hr) were covariates for opioid consumption analyses. Same 
covariates were included in pain analyses in addition to preoperative pain and opioid 
consumption during the first 45 minutes in the PACU (mg/kg). Since the frequencies of alleles 
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and haplotypes may vary among the different ancestries, we also conducted a subgroup analysis 
limited to Caucasian subjects (n=121). All analyses were carried out using IBM® SPSS® 
Statistics version 22 (IBM Corporation, Armonk, NY) and a two-sided p-value of less than 0.05 
was considered to be statistically significant. Due to the exploratory nature of current data 
analyses, no multiple comparisons adjustment was made.   
6.3.5 Source of funding 
The parent study was funded by the American Association of Nurse Anesthetist Foundation, as 
well as a grant (UL1 RR024153) from the National Institutes of Health (NIH). This study was 
funded by the Margaret E. Wilkes scholarship fund award from University of Pittsburgh School 
of Nursing. 
6.4 RESULTS 
6.4.1 Demographic characteristics 
The sample of postoperative patients (N=153) who underwent surgical orthopedic trauma repair 
was mostly male (n=104, 68%), non-Hispanic Caucasian (n=121, 80%), and nonsmokers (n=86, 
57%) and on average (±SD) 38.48 ±13.1 years of age. Further description of the entire sample is 
presented in Table 14. Caucasian sample description is provided in Table 15. 
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6.4.2 Genetic characteristics 
Genotype and allele frequencies of OPRM1 and COMT SNPs are presented in Table 16. Three of 
the four COMT SNPs (rs4680, rs4633, and rs6269) displayed significant deviation from HWE as 
shown in Table 16. COMT SNPs were out of equilibrium even after restricting our analyses to 
Caucasian patients. Systematic lab review of raw genotype data was performed to examine if 
deviations from HWE were due to genotyping error. Pairwise linkage disequilibrium values 
computed by Haploview software showed that all COMT SNPs (rs4680, rs4633, rs4818and 
rs6269) were in strong LD (D' > 0.75) (Figure 11). The distribution of COMT haplotypes and 
diplotypes were as follow; 52 (39%) patients had no copy of LPS haplotype and 82 (61%) had at 
least one copy; 63 (47%) patients had no copy of APS haplotype and 71 (53%) had at least one 
copy; 110 (82%) patients had no copy of HPS haplotype and 24 (18%) had at least one copy. 
Regarding the COMT diplotypes; 77 (57%) patients had the low pain sensitivity diplotype and 57 
(43%) had the high pain sensitivity diplotype. 
6.4.3 OPRM1 × COMT interaction on PACU opioid consumption 
Regression analysis results for predicting PACU opioid (mg/kg) consumption by OPRM1× 
COMT are reported in the Table 17. A significant interaction was found between COMT 
Val158Met (rs4680) when assuming a recessive genetic model (Met158Met vs. 
Val158Met/Val158Val) and OPRM1 A118G assuming a dominant genetic model 
(A118G/G118G vs. A118A), beta = 0.093 (95%CI [0.006, 0.179]), p < .05. We found that 
patients having Met158Met (AA) of COMT rs4680 and (AG/GG) of OPRM1 A118G consumed 
the largest amount of opioids compared to other combinations (Figure 12).  
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A significant interaction was also found between COMT rs4633 assuming a recessive 
genetic model (TT vs. CT/CC) and OPRM1 A118G, b = 0.097 (95% CI [0.006, 0.189]), p < .05. 
We found that patients having TT of COMT rs4633 and (AG/GG) of OPRM1 A118G consumed 
the largest opioids compared to other combinations (Figure 13). OPRM1 A118G×COMT rs4680 
and OPRM1 A118G×COMT rs4633 accounted uniquely for 3.1% and 3.3% of the variance in 
total PACU opioid consumption, respectively. No significant interactions were found between 
OPRM1 A118G and the other two SNPs of COMT rs6269 and rs4818. However, the interaction 
of COMT rs6269 and OPRM1 demonstrated a trend (p = .08). Patients who have AA of COMT 
rs6269 and AG/GG of OPRM1 A118G consumed more opioids compared to other combination, 
b = -0.075, 95%CI [-0.16, 0.01]. 
No significant interaction was found between OPRM1 and COMT haplotypes or 
diplotypes. However, the interaction of COMT diplotype and OPRM1 demonstrated a trend 
towards significance (p = .07). Patients having high pain sensitivity diplotype and (AG/GG) of 
OPRM1 A118G seemed to consume more opioids compared to other combinations, b = 0.071, 
95%CI [-0.006, 0.148]. Restricting our analysis to Caucasian subjects did not change the 
direction or the statistical significance for the interaction effects of both OPRM1 A118G×COMT 
rs4680 and OPRM1 A118G×COMT rs4633 on PACU opioid consumption (data not shown). 
6.4.4 OPRM1 × COMT interaction on postoperative pain in PACU 
Regression analysis results for predicting postoperative pain ratings (square root transformed) by 
OPRM1 × COMT are summarized in Table 18. A significant interaction was found between 
COMT LPS (GCGG) haplotype and OPRM1 A118G, beta = -0.93 (95%CI [-1.686, -0.166]), p < 
.05. The effect of OPRM1 on postoperative pain ratings varied across levels of COMT LPS 
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haplotype. For patients with no copies of LPS haplotype, the wild type of OPRM1 A118G (AA) 
was significantly associated with higher pain scores compared to the variant (AG/GG). For 
patients who have at least one copy of LPS haplotype, (AA) of OPRM1 A118G was significantly 
associated with lower pain score compared with those having the variant (AG/GG) (Figure 14). 
OPRM1A118G×COMT LPS haplotype accounted uniquely for 3.7% of the variance in total 
postoperative pain ratings. No significant interaction was found among OPRM1 and other COMT 
haplotypes and dipolotypes. No significant interaction was found between OPRM1 and COMT 
SNPs; however, the interaction of COMT rs4818 and OPRM1 assuming dominant genetic 
models demonstrated a trend near significance (p = .06).  
Analyses of the main effect of COMT showed that patients with high pain sensitivity 
COMT diplotype reported significantly higher postoperative pain scores compared to patients 
with low pain sensitivity diplotype, beta = -0.32 (95%CI [-0.636, -0.005]), p < .05. Moreover, 
the main effect of COMT rs4633, assuming a recessive genetic model, was significantly 
associated with postoperative pain in the PACU, beta = -0.389 (95%CI [-0.759, -0.019), p<0.05. 
Patients with two minor alleles T (TT) reported significantly higher postoperative pain scores at 
45 minutes in PACU compared to patients with CT or CC. The main effect of COMT rs4818, 
assuming a dominant genetic model, was also significantly associated with postoperative pain, 
beta = 0.38 (95%CI [0.051, 0.723]), p < .05. Patients with one or two minor alleles G (GC and 
GG) reported significantly higher postoperative pain scores compared to patients with CC, 
Assuming recessive genetic models, the main effects of COMT rs4680 and rs6269 showed a 
trend toward significance with p-values of .063 and .055, respectively. 
Restricting the analyses to Caucasian subjects, none of OPRM1 A118G×COMT SNPs, 
haplotypes and diplotypes were significantly associated with postoperative pain. However, the 
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interaction effects for OPRM1 A118G×COMT LPS, OPRM1A118G×COMT HPS, and OPRM1 
A118G×COMT diplotypes were near significant (p= .070, p= .058, p= .050, respectively).  
6.5 DISCUSSION 
Our findings provide the first evidence that OPRM1 A118G × COMT (four SNPs as well as their 
haplotypes and diplotypes) interactions may explain the variability in postoperative pain and 
response to opioids. Several important conclusions can be drawn. First, combining the mutant 
variant of both OPRM1 A118G and COMT Val158Met is associated with poor response to 
opioid analgesia. We found that patients with combined Met158Met of COMT Val158Met and 
(AG/GG) of OPRM1 A118G consumed more opioid compared to patients with other 
combinations. These findings suggest that combining both variants results in synergistic effect 
associated with poor response to opioid therapy. Consistent with previous work of Reyes-Gibby 
et al, we also found that carriers of the OPRM1 AA and COMT Met/Met genotype required the 
lowest opioid dose compared to other combinations.  
Second, synonymous SNPs of the COMT gene might influence pain sensitivity. It has 
been found that synonymous” silent” SNPs of COMT gene could affect mRNA stability and 
consequently COMT protein expression and enzymatic activity (Nackley et al., 2006). Consistent 
with that, we found that the two synonymous SNPs of COMT, rs4633 and rs4818, were 
significantly associated with postoperative pain in PACU. TT of rs4633 and AG/GG of rs4818 
were associated with high pain sensitivity.  
Third, COMT haplotypes/ diplotypes have greater impact on pain than single SNPs. 
Recent genetic studies focused on investigating haplotype reconstruction suggesting that 
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combinations/ interactions of SNPs within haplotypes lead to synergistic effects on the resultant 
protein and it might result in functional consequences that is different from the independent 
effect of those SNPs (Diatchenko et al., 2005; Duan et al., 2003). For instance, LPS and HPS 
haplotypes of COMT are identical for Val158Met, both of which have the Val allele. However, 
they significantly differ in the resultant protein and enzyme activity. LPS shown to catabolize 
catecholamine 11.4 times higher than HPS and decrease pain sensitivity (Diatchenko et al., 
2006). This suggests that the interactions of multiple SNPs within COMT haplotype determines 
the functional outcomes of COMT enzyme rather than only single SNP of Val158met. Our main 
effect analysis findings suggested that the single SNP Val158Met was not associated with 
postoperative pain; however, COMT diplotypes were significantly associated with postoperative 
pain.  
Fourth, the LPS haplotype has a “protective” effect on pain when combined with the wild 
type of OPRM1. We have shown that having at least of one copy of LPS haplotype and wild type 
of OPRM1 A118G was associated with lower postoperative pain scores compared to variant 
(AG/GG), yet not carrying the LPS haplotype was associated with the opposite direction. The 
reasons for this dichotomy are unclear. Thus, additional research is required to establish the exact 
mechanisms influencing these relationships. 
Finally, racial differences in allele and haplotype frequencies may influence 
postoperative pain sensitivity. Our findings on postoperative pain were changed after restricting 
the analyses to Caucasians. The interaction of OPRM1 and LPS haplotype was not significant in 
Caucasians; however, the interaction effectwas similar to that for total sample. OPRM1×ACCG 
and OPRM1×diplotypes showed a trend toward significance that was not observed using the total 
sample. None of the significant main effect of COMT rs4818, COMT rs4633, or COMT 
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diplotypes were significant in the Caucasian-only sample. The changes in our findings might be 
partly due to the variation in the allele and haplotype frequencies among the different racial 
populations. The G allele frequencies of OPRM1 A118G vary across racial and ethnic groups, it 
ranges from 12% to 20% in Caucasians, 1% to 4% in African Americans, and 19% to 24% in 
Hispanics (Hastie et al., 2012). COMT allele frequencies and COMT haplotype structures and 
frequencies also vary among the different racial groups (Beuten et al., 2006; DeMille et al., 
2002; Gabriel et al., 2002; Palmatier et al., 1999). Moreover, one study found that COMT 
enzyme activity was significantly higher in African American compared to Caucasian (McLeod, 
Fang, Luo, Scott, & Evans, 1994).  
Our study has several limitations. While our sample size is larger than what was reported 
in the literature in the pain area (Kolesnikov et al., 2011; Landau et al., 2013), it is still relatively 
small for general genetic study of a common phenotype. However, even with this small sample 
size, it appears that significant associations exist. Three of the COMT SNPs were out of HWE; 
however, it is possible that deviation from HWE is due to the distinctive characteristics of our 
sample. Our sample may not be completely representative of the general population. Despite 
violations of HWE, COMT SNPs are genetically related (i.e., in strong LD) and they collectively 
influence the biological process of pain.  
6.6 CONCLUSION 
Our findings suggest the OPRM1×COMT may contribute to variability of postoperative pain and 
response to opioids. Incorporation of diagnostic markers such as OPRM1 and COMT will 
potentially facilitate the identification of high-risk individuals for opioid mismanagement. 
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Consequently, opioid therapy can be individualized for better pain management. Future studies 
with larger sample sizes and more diversity are needed to confirm these effects. 
6.7 FIGURES AND TABLES  
 
 
Figure 11. Linkage disequilibrium (LD) graph of COMT SNPs 
 
 
 
 
 
 
 
 
Linkage disequilibrium (LD) graph of COMT SNPs “left” and Haplotype frequency “right”. LD was calculated using D' (0= 
no disequilibrium; 1= maximum disequilibrium). The numbers inside the squares are 100 × D'. Graph was created using 
Haploview software. LPS= Low pain Sensitivity; APS= Average pain Sensitivity; HPS= High pain Sensitivity 
 
 
100 
Figure 12. The interaction of OPRM1 A118G × COMT rs4680 on PACU opioid consumption for the 
total sample
Graphs display the OPRM1 × COMT interaction for the typical participant in our sample; Caucasian, male, with ankle 
fracture, age of 39.9 years, and OR opioid consumption of 0.233mg/kg/hr.
Figure 13. The interaction of OPRM1 A118G × COMT rs4633 on PACU opioid consumption for the 
total sample
Graphs display the OPRM1 × COMT interaction for the typical participant in our sample; Caucasian, male, with ankle fracture, 
age of 39.9 years, and OR opioid consumption of 0.233mg/kg/hr.
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Table 14. Descriptive statistics for the total sample (n=153) 
Variable Descriptive statistics 
Age (years) 38.48 ± 13.13 
Gender (Male) 104 (68) 
Ethnicity (Caucasian) 121 (80) 
Smoking (non-smoker) 86 (57) 
Body Mass Index (kg/m2) 29.09 ± 7.43 
Fracture type 
Ankle 
Femur 
Tibial plateau 
Tibia-fibula 
Other 
56 (39) 
16 (11) 
30 (21) 
35 (24) 
7 (5) 
Surgical time (min) 120.00 ± 59.51 
PACU time (min) 125.30 ± 48.00 
Preoperative Numerical Pain scale score 4.56 ± 2.95 
Postoperative Numerical Pain scale score at 45 min in PACU 6.48 ± 2.70 
Opioid consumption during OR (mg) 35.86 ± 18.17 
Opioid consumption during the first 45 min in PACU (mg) 6.80 ± 5.41 
Opioid consumption during PACU stay (mg) 9.60 ± 7.74 
Descriptive statistics reported in cell are expressed as M ± SD for continuous variables and n (%) for categorical 
variables. OR = Operation Room; PACU = Post Anesthesia Care Unit. 
Figure 14. The interaction of OPRM1 × COMT Low Pain Sensitivity (LPS; GCGG) haplotype 
on postoperative pain ratings at 45 minutes in PACU for the total sample
Graphs display the OPRM1 × COMT interaction for the typical participant in our sample; Caucasian, male, with ankle fracture, 
age of 39.9 years, and OR opioid consumption of 0.233mg/kg/hr.
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Table 15. Descriptive statistics for the Caucasian sample (n=121) 
Variable Descriptive statistics  
Age (years) 39.85 ± 13.16 
Gender (Male) 88 (73) 
Smoking (non-smoker) 69 (58) 
Body Mass Index (kg/m2) 29.60 ± 6.83 
Fracture type 
Ankle 
Femur 
Tibial plateau 
Tibia-fibula 
Other 
 
44 (38) 
14 (12) 
25 (22) 
25 (25) 
7 (6) 
Surgical time (min) 120.00 ± 59.51 
PACU time (min) 126.11 ± 61.73 
Preoperative Numerical Pain scale score 4.44 ± 2.73 
Postoperative Numerical Pain scale score at 45 min in PACU 6.23 ± 2.76 
Opioid consumption during OR (mg) 35.08 ± 17.04 
Opioid consumption during the first 45 min in PACU (mg) 6.87 ± 5.62 
Opioid consumption during PACU stay (mg) 10.11 ± 7.74 
Descriptive statistics reported in cell are expressed as M ± SD for continuous variables and n (%) for categorical 
variables. OR = Operation Room; PACU = Post Anesthesia Care Unit. 
 
 
Table 16.  Genotype and allele frequency of OPRM1 and COMT SNPs 
    Allelesa  Genotypes  
Gene SNP Chromosome Position A1 A2 MAFb A1/A1 A1/A2 A2/A2 HWEc 
OPRM1 rs1799971 6 154360797 G A 0.1176 2 28 106 1 
COMT rs4680 22 19951271 A G 0.4412 37 46 53 0.00025 
 rs4633 22 19950235 T C 0.4286 33 48 52 0.00258 
 rs4818 22 19951207 G C 0.4427 30 56 45 0.15560 
 rs6269 22 19949952 A G 0.4924 40 49 42 0.00494 
aA1: Minor allele; A2: Major allele; bMAF: Minor Allelic Frequency; cHardy-Weinberg Equilibrium (HWE) test p-
value. 
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Table 17. Regression analysis results for predicting PACU opioid (mg/kg) consumption by OPRM1×COMT 
Interaction Variable Sample n beta 95%CI p-value sr2 
 
OPRM1 A118G×COMT rs4680 
 
 
Total 
Caucasians 
 
 
123 
96 
 
0.093 
0.108 
 
(0.006,0.179) 
(0.017,0.200) 
 
.037 
.021 
 
.031 
.047 
OPRM1 A118G×COMT rs4633  
 
Total 
Caucasians 
 
120 
93 
0.097 
0.102 
(0.006,0.189 ) 
(0.006,0.199) 
.037 
.038 
.033 
.039 
OPRM1 A118G×COMT rs4818  
 
Total 
Caucasians 
 
119 
93 
-0.044 
-0.058 
(-0.126,0.037) 
(-0.153,0.036) 
.284 
.223 
.009 
.014 
OPRM1 A118G×COMT rs6269 
 
Total 
Caucasians 
118 
92 
 
-0.075 
-0.070 
(-0.160,0.010) 
(-0.163,0.023) 
.082 
.136 
.023 
.021 
OPRM1 A118G×COMT LPS 
haplotype (GCGG) 
 
 
Total 
Caucasians 
123 
96 
-0.047 
-0.059 
(-0.125,0.030) 
(-0.149,0.031) 
.230 
.194 
.011 
.015 
OPRM1 A118G×COMT APS 
haplotype (ATCA) 
 
Total 
Caucasians 
 
123 
96 
0.009 
-0.015 
(-0.068,0.086) 
(-0.1060,.077) 
.818 
.750 
<.001 
<.001 
OPRM1 A118G×COMT HPS 
haplotype (ACCG) 
 
 
Total 
Caucasians  
123 
96 
0.001 
-0.073 
(-0.095,0.098) 
(-0.191,0.045) 
.982 
.222 
<.001 
.013 
OPRM1 A118G×COMT 
Diplotypes 
Total 
Caucasians  
123 
96 
0.071 
0.047 
(-0.006,0.148) 
(-0.040,0.135) 
.070 
.285 
.024 
.010 
In addition to the OPRM1×COMT interaction, models included the main effects of both OPRM1 and COMT, gender, 
race, age, smoking, fracture type and OR opioid consumption. LPS= Low pain Sensitivity; APS= Average pain 
Sensitivity; HPS= High pain Sensitivity. 
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Table 18. Regression analysis results for predicting postoperative pain ratings by OPRM1×COMT  
 
Interaction Variable Sample n beta 95%CI p-value sr2 
 
OPRM1 A118G×COMT rs4680  
 
 
Total  
Caucasians 
  
 
192 
95  
 
0.444 
0.421 
 
(-0.436,1.324) 
(-0.501,1.342) 
 
.319 
.366 
 
.007 
.007 
OPRM1 A118G×COMT rs4633  
 
Total  
Caucasians 
  
118 
92 
 
0.359 
0.419 
(-0.559,1.276) 
(-0.526,1.364) 
.440 
.380 
.004 
.007 
OPRM1 A118G×COMT rs4818  
 
Total  
Caucasians 
 
117 
92 
-0.755 
-0.486 
(-1.543,0.033) 
(-1.390,0.420) 
.060 
.128 
.024 
.020 
OPRM1 A118G×COMT rs6269  
 
 
Total  
Caucasians 
116 
91 
-0.500 
-0.640 
(-1.297,0.296) 
(-1.470,0.188) 
.216 
.128 
.010 
.020 
OPRM1 A118G×COMT LPS 
haplotype (GCGG) 
 
Total  
Caucasians 
121 
95 
-0.926 
-0.794 
(-1.686,-0.166) 
(-1.66,0.067) 
.017 
.070 
.037 
.023 
       
OPRM1 A118G×COMT APS 
haplotype (ATCA) 
 
 
Total  
Caucasians  
121 
95 
0.288 
0.080 
(-0.510,1.085) 
(-0.811,0.971) 
.476 
.858 
.003 
<.001 
OPRM1 A118G×COMT HPS 
haplotype (ACCG) 
 
 
Total  
Caucasians  
121 
95 
0.596 
1.110 
(-0.372,1.563) 
(-0.04,2.261) 
.225 
.058 
.010 
.031 
OPRM1 A118G× COMT 
Diplotypes 
 
Total  
Caucasians 
121 
95 
0.637 
0.831 
(-0.132,1.407) 
(-0.001,1.662) 
.103 
.050 
.017 
.033 
In addition to the OPRM1×COMT interaction, models included the main effects of both OPRM1 and COMT, 
gender, race in total sample, age, smoking, fracture type, preoperative pain, OR opioid consumption and opioid 
consumption during the first 45 minutes in PACU.  LPS= Low pain Sensitivity; APS= Average pain Sensitivity; 
HPS= High pain Sensitivity. 
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